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ABSTRACT 
REDOX TRIGGERING OF PODOCYTE NLRP3 INFLAMMASOMES AND GLOMERULAR 
INJURY IN HYPERHOMOCYSTEINEMIA 
 
By Justine M. Abais 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy at Virginia Commonwealth University 
 
Virginia Commonwealth University, 2014 
 
Major Director: Pin-Lan Li, MD, PhD, Professor, Pharmacology and Toxicology 
 
Hyperhomocysteinemia (hHcys), an important pathogenic factor contributing to the progression 
of end-stage renal disease (ESRD), has been shown to activate NOD-like receptor protein 3 
(NLRP3) inflammasomes and cause podocyte dysfunction and glomerular sclerosis. hHcys 
induces aggregation of the three inflammasome components – NLRP3, apoptosis-associated 
speck-like protein (ASC), and caspase-1 – and its activation is indicated by increased caspase-1 
activity and secretion of interleukin-1β (IL-1β). The aims of the present study sought to elucidate 
the role of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase-mediated redox 
signaling in hHcys-induced NLRP3 inflammasome activation, to dissect the contribution of 
common endogenous reactive oxygen species (ROS) including superoxide (O2
•−
), hydrogen 
peroxide (H2O2), peroxynitrite (ONOO
−
), and hydroxyl radical (
•
OH), and to explore the 
molecular mechanisms by which the NLRP3 inflammasome senses changes in oxidative stress 
through thioredoxin-interacting protein (TXNIP). Specific inhibition of the gp91
phox
 subunit of 
NADPH oxidase markedly reduced Hcys-induced caspase-1 activity and IL-1β production in 
cultured podocytes. Concurrently, gp91
phox−/−
 or administration of a gp91ds-tat peptide also 
exhibited diminished glomerular inflammasome formation and activation in mice fed a folate-
free (FF) diet to induce hyperhomocysteinemia and displayed glomerular protection as shown by 
 XV 
prevention of hHcys-induced proteinuria, albuminuria and glomerular sclerosis.  Interestingly, 
dismutation of O2
•− 
by 4-Hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl and administration of 
H2O2 decomposer catalase either in cultured podocytes or hyperhomocysteinemic mice inhibited 
hHcys-induced NLRP3 inflammasome aggregation and activation. Hyperhomocysteinemic mice 
also demonstrated a significant increase in glomerular TXNIP binding to NLRP3, confirmed by 
confocal microscopy, size-exclusion chromatography, and co-immunoprecipitation studies. 
Blockade of TXNIP by genetic interference or by the calcium channel blocker verapamil 
prevented this hHcys-induced TXNIP-NLRP3 binding, NLRP3 inflammasome formation and 
activation, as well as protected hyperhomocysteinemic mice from glomerular dysfunction and 
damaged morphology. In conclusion, hHcys-induced NADPH oxidase activation is importantly 
involved in the switching on of NLRP3 inflammasomes in podocytes, where NADPH oxidase-
derived O2
•−
 and H2O2 primarily contribute to NLRP3 inflammasome activation. TXNIP binding 
to NLRP3 is a key signaling mechanism allowing NLRP3 inflammasome to sense these changes 
in oxidative stress. These findings greatly enhance our understanding of the early pathogenesis of 
hHcys-induced glomerular sclerosis, which may identify new therapeutic targets for prevention 
or treatment of ESRD. 
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CHAPTER ONE 
INTRODUCTION 
 
Hyperhomocysteinemia (hHcys) has been reported to be an important pathogenic factor leading 
to the progression of end-stage renal disease (ESRD) and related cardiovascular complications 
associated with aging and different diseases [1-6].  Despite extensive studies, the mechanisms 
mediating the pathogenic actions of hHcys are not yet fully understood.  Recent studies in our 
laboratory provided evidence that hHcys may generate its detrimental effects by activation of a 
NOD-like receptor protein (NLRP3)-centered inflammasome in podocytes. The activation of 
NLRP3 inflammasomes in podocytes turns on the inflammatory response, causing chronic 
inflammation in glomeruli and ultimately leading to glomerular dysfunction and sclerosis.  It has 
been proposed that the activation of podocyte NLRP3 inflammasomes during hHcys is a critical 
mechanism inducing kidney senescence and progressive degenerative glomerular dysfunction 
and sclerosis [7]. However, it remains to be determined how the NLRP3 inflammasomes are 
formed and activated during hHcys and how activated NLRP3 inflammasomes induce 
glomerular degenerative pathology ultimately leading to end-stage renal disease (ESRD). The 
current project provided convincing evidence suggesting that elevated extracellular Hcys 
concentrations activate NADPH oxidase to produce reactive oxygen species (ROS) and thereby 
activate NLRP3 inflammasomes in podocytes and increase the downstream recruitment of 
inflammatory cells in glomeruli, resulting in local inflammation and ultimate glomerular 
sclerosis. This redox activation of podocyte inflammasomes associated with hHcys may 
represent an early mechanism switching on local inflammatory responses in glomeruli. The 
following section will review our current understanding of hyperhomocysteinemia, NADPH 
 2 
oxidase in the kidney, and the regulation of NLRP3 inflammasomes and their interactions as it 
pertains to the development of hHcys-induced glomerular injury and ESRD. 
 
1.1 Hyperhomocysteinemia 
A considerable amount of evidence indicates that plasma homocysteine (Hcys) levels are 
elevated in patients with ESRD, where hyperhomocysteinemia (hHcys) occurs in about 85% of 
chronic kidney disease patients due to impairments in Hcys metabolism and excretion [8-10]. 
These complications associated with hHcys have also been reported in a wide range of chronic 
pathological conditions, including vascular dysfunction, neurological diseases, metabolic 
disorders, the development of cancer, and many complications associated with aging [11-17]. In 
the kidney, hHcys has been known to directly cause deleterious effects, promoting a vicious 
cycle responsible for chronic kidney disease, where hHcys decreases renal function and leads to 
further increased plasma Hcys levels due to decreases in Hcys excretion in the kidney [18]. In 
humans, a plasma Hcys concentration <10μM is considered to be within the normal range, 10-16 
μM is clinically defined as mild hHcys, 16-30 μM as moderate hHcys, 30-100 μM as 
intermediate hHcys, and >100μM as severe hHcys [18]. 
 
1.1.1 Homocysteine metabolism 
Homocysteine is a thiol-containing, nonessential amino acid derived from the metabolism 
of the essential amino acid methionine. Upon activation of methionine by ATP, S-adenosyl-
methionine (SAM) undergoes demethylation to form S-adenosyl-homocysteine (SAH). This 
reaction makes SAM a major methyl group donor for many reactions including the methylation 
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of DNA. SAH is then subsequently hydrolyzed to form Hcys and adenosine by SAH hydrolase 
[9]. 
 
As depicted in Figure 1, the remethylation of Hcys back to methionine or its 
transsulfuration to cysteine are the two major catabolic pathways metabolizing Hcys. The 
remethylation pathway involves the enzyme methionine synthase (MS) using N
5
-
methyltetrahydrofolate (5-MTHF) as the methyl donor that requires cobalamin (vitamin B12), as 
well as the enzyme methylenetetrahydrofolate reductase (MTHFR) that requires folates as an 
essential cofactor for the reduction and formation of 5-MTHF. The transsulfuration of Hcys is 
carried out via two enzymes, cystathionine-β-synthase (CBS) and γ-cystathionase. Together with 
serine, Hcys first undergoes irreversible condensation by CBS using pyridoxal-5-phosphate 
(vitamin B6) as a cofactor. Cystathionine is then further broken down by γ-cystathionase into 
cysteine, and converted into sulfates that are then excreted in the urine. The liver and kidney are 
two major sites of Hcys metabolism, with an estimated ~70% of Hcys clearance occurring in the 
kidneys [19-21]. 
 
There are multiple ways by which Hcys can become elevated [22]. First, an overwhelming 
intake of methionine-rich animal protein not only overwhelms the transsulfuration pathway, but 
can also lead to inhibition of the remethylation pathway due to the existing overload of 
methionine. Second, nutritional deficiencies in the cofactors required for these reactions may 
result in enzymatic dysfunction, thus impairing either pathway of Hcys clearance. This was 
substantiated in the Framingham Heart Study, where elderly patients deficient in vitamin B6 and 
folates exhibited hHcys and arteriosclerosis [23]. Finally, genetic polymorphisms in the enzymes 
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themselves have been identified in ESRD patients, where mutations in the MTHFR enzyme are 
correlated with increased plasma level of Hcys [24-25] and are also indicative of the patients‟ 
response to Hcys-lowering therapies. 
 
1.1.2 Pathogenic role of hHcys in ESRD 
Recognition of hHcys as a detrimental risk factor came from the early pioneer work carried 
out by Dr. Kilmer S. McCully in the 1960s on the role of deficient Hcys-metabolizing enzymes 
in childhood arteriosclerosis, and was the first to propose that elevated Hcys directly causes 
arterial damage [3]. This seminal work has since expanded from arteriosclerosis and 
cardiovascular disease to include many other degenerative diseases and pathological processes. 
 
 
Figure 1. Homocysteine metabolism. When methionine is activated by ATP, S-adenosyl-
methionine (SAM) undergoes demethylation to form S-adenosyl-homocysteine (SAH). SAH 
is then subsequently hydrolyzed to form Hcys and adenosine by SAH hydrolase. 
Homocysteine levels are regulated through its remethylation back to methionine by 
methionine synthase (MS) or its transsulfuration to cysteine by cystathionine β-synthase. 
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Numerous clinical and epidemiological studies demonstrated positive correlations between 
elevated plasma Hcys with ESRD and its related cardiovascular complications [26-30]. In nearly 
every clinical study where plasma Hcys levels were measured in patients with renal 
complications, there was a strong positive correlation between plasma levels of Hcys and serum 
creatinine, a marker for declining renal function [31]. Additionally, these patients exhibited 
plasma Hcys concentrations three to five times higher than healthy controls [32-34].  
 
Despite the strong associations made between ESRD and the prevalence of hHcys, the 
mechanisms underlying Hcys-induced pathogenesis of glomerular injury and dysfunction are still 
poorly understood. The detrimental or sclerotic actions of hHcys have been attributed to altered 
extracellular matrix metabolism, reduced protection from nitric oxide (NO), and increased 
production of ROS. With a diminished capacity to maintain the extracellular matrix (ECM) [7, 
35-38], hyperhomocysteinemic conditions cause a serious imbalance in matrix synthesis and 
degradation, resulting in vascular remodeling. Besides alterations in ECM metabolism, Hcys has 
been shown to alter the local oxidative state and elevate levels of superoxide (O2
•−
) by 
uncoupling NO synthase, directly trapping NO itself, and activating NADPH oxidase, the 
dominant source of O2
•− 
in many non-phagocytic cells, especially in the kidney [39-43]. 
Together, these effects of inhibiting extracellular matrix degradation and the production of local 
oxidative stress all contribute to the sclerotic process that eventually leads to the loss of renal 
function [37-38]. 
 
Studies from our laboratory and by others have demonstrated that hHcys directly induces 
glomerular injury, affecting glomerular endothelial cells, mesangial cells, and podocytes [44-46].  
 6 
Mechanistically, our laboratory has shown that hHcys-induced glomerular sclerosis and ultimate 
ESRD involve N-methyl-D-aspartate (NMDA) receptor activation and occur in an nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidase-dependent manner, which is associated with 
the activation of small GTPase Rac1 and guanine nucleotide exchange factor Vav2 [7, 38, 44].  
Additionally, our laboratory has provided substantial evidence that increases in ROS production 
are a result from activation of NADPH oxidase by Hcys [7-8, 47]. It has been shown that 
knockout of the gp91
phox
 gene, a catalytic subunit of NADPH oxidase, is protective towards 
Hcys-induced glomerular injury in mice [48], preventing the accumulation of O2
•− 
and 
consequent podocyte damage, attenuating proteinuria, and preserving glomerular filtration rate 
when compared to hyperhomocysteinemic wild-type mice. These results suggest a crucial role 
for functioning NADPH oxidase in the sclerotic mechanism of hHcys during the progression of 
glomerular injury. Most recently, Nod-like receptor protein 3 (NLRP3) inflammasome-mediated 
caspase-1 activation and IL-1β production were found to be necessary for hHcys-induced 
podocyte and glomerular dysfunction, where inhibition of NLRP3 inflammasomes either by 
apoptosis-associated speck-like protein (ASC) gene silencing or pharmacological inhibition of 
caspase-1 attenuated hHcys-induced injury [49]. However, further studies are warranted to fully 
understand the mechanisms mediating Hcys-induced NLRP3 inflammasome activation and its 
contribution to glomerular injury. 
 
1.1.3 Murine models of hHcys 
hHcys can be experimentally modeled in animals through dietary and genetic 
manipulations, modifications, or a combination of the two. In order to hereditarily model hHcys, 
the mouse genes for the enzymes CBS, MTHFR, and MS have been genetically modified. 
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CBS
−/−
 mice exhibit severely elevated levels of plasma Hcys (>200 μM), but rarely survive 
beyond 3-5 weeks of age due to the severity of hHcys [50]. Therefore, the use of heterozygous 
CBS mice, which develop mild hHcys, is much more common [50-52]. MTHFR
−/− 
mice, 
developed in 2001, only exhibit moderate hHcys but also undergo difficulties in survival after 
just 5 weeks of age [53-54]. Finally, homozygous knockout of the Mtr gene, which encodes the 
enzyme MS, is embryonic lethal, but heterozygous mutation only produces mild hHcys (5-10 
μM) [55]. The advantage of these genetic models is the avoidance of potential side effects that 
may arise from the global deficiency of essential cofactors, thereby making these genetic 
approaches commonly used.  
 
In regards to dietary approaches used to elevate plasma Hcys, these interventions include 
directly adding Hcys to the drinking water, overwhelming the metabolic pathway depicted in 
Figure 1 through administration of a high-methionine diet, limiting Hcys transsulfuration by 
restricting dietary intake of vitamin B6, or limiting Hcys remethylation back to methionine 
through a folate or vitamin B12-deficient deficient diet. However, excessive plasma methionine is 
not a clinically observed phenomenon in patients with hHcys, thereby limiting the translational 
validity of the high-methionine diet. Generally, human patients with hHcys display deficiencies 
in folate, vitamin B6, or vitamin B12, making these particular diet-induced experimental models 
of hHcys directly relevant to the human condition [56]. Therefore, a model of folate-free (FF) 
diet-induced hHcys was selected for the current study. 
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1.2 NADPH oxidase in the kidney 
Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, an enzyme generating 
O2
•−
 from oxygen and NADPH, can primarily be found in phagocytic cells, where its primary 
role is to generate large amounts of reactive oxygen to carry out traditional immune functions 
[57]. However, this enzyme and its isoforms are also found spread throughout various organs, 
where its primary function is not for defense and to kill non-host organisms, but instead to 
produce small amounts of O2
•−
 to act a signaling messengers [58]. In the kidney, there are many 
enzymatic systems that contribute to the production of ROS, including mitochondrial oxidases, 
xanthine/xanthine oxidase, lipoxygenases, cyclooxygenases, and cytochrome P450s. However, 
unlike these other systems where the production of O2
•−
 is a secondary process, NADPH oxidase 
is the only enzyme identified to produce O2
•−
 as its principal function. NADPH oxidase has been 
considered as the major source of O2
•−
 in the kidney, specifically in the renal cortex [39]. Its 
action relies on an enzymatic complex with five subunits including two membrane-associated 
flavocytochrome components (gp91
phox
 and p22
phox
), three cytosolic components (p40
phox
, 
p47
phox
, p67
phox
), and a GTPase, Rac1, all being reported to be expressed in the kidney [39]. 
When stimulated, the translocation of its cytosolic components to the subunits in the membrane 
results in the transfer of electrons from NADPH to form O2
•−
 from oxygen. The generation of 
O2
•−
 by NADPH oxidase is the precursor for other species of reactive oxygen, including 
hydrogen peroxide, hydroxyl radical, peroxynitrite, hypochlorous acid, and singlet oxygen [58-
61]. Interestingly, our laboratory and others have found increased local oxidative stress, for the 
most part mediated through NADPH oxidase, to be strongly associated with the cardiovascular 
complications related to ESRD as well as with the damaging effects of hHcys [47, 62-65].  
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1.2.1 Regulation of NADPH oxidase by Rac1 GTPase and GEF Vav2 
The activation of NADPH oxidase is dependent on the aggregation of its membrane and 
cytosolic components to the plasma membrane, which requires phosphorylation of the p47
phox
 
subunit, its translocation to the membrane along with the remaining cytosolic subunits, protein-
protein interactions between all components, and Rac GTPase activation [66-68]. Rac1 is a 
member of the Rho-family of GTPases which are binary switches important for the regulation of 
many cellular functions including cell cycle progression, apoptosis, differentiation, adhesion, and 
migration and vesicle trafficking through control of actin polymerization [69-71]. In 1991, Abo 
et al identified phagocytic NADPH oxidase to be the first Rac effector [72]. Since then, a central 
role for Rac, in particular, Rac1, has been established in the regulation and activation of NADPH 
oxidase. 
 
NADPH oxidase activation and production of O2
•−
 are dependent on the switching of Rac1 
between two conformations – the active GTP-bound and inactive GDP-bound states. The cycling 
of Rac1 between these two states is highly and mainly regulated by GTPase-activating proteins 
(GAPs) and guanine nucleotide exchange factors (GEFs). GAPs promote GTP hydrolysis and 
push GTPases to the inactive GDP-bound state, while GEFs facilitate the exchange of GDP for 
GTP to promote the active GTP-bound state [73]. With over 30 GEFs identified, the Vav 
subfamily of GEFs has been shown to exhibit high specificity to and importantly regulate Rac 
GTPase and NADPH oxidase [74-77]. 
 
 With substantial evidence our laboratory has demonstrated these NADPH oxidase-
activating pathways to be involved in Hcys-induced glomerular injury. These previous studies 
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have shown that through de novo ceramide synthesis, Hcys stimulated NADPH oxidase 
activation by enhancing Rac GTPase activity in rat mesangial cells [65]. Furthermore, inhibition 
of GEF Vav2, the predominant isoform was found to be expressed in these cells, prevented 
Hcys-induced increase in Rac1 activity and consequent activation of NADPH oxidase [38, 44]. 
Together, these results signify the importance of Rac1 and its regulation by Vav2 in the 
development of hHcys-induced production of oxidative stress and glomerular injury. However, 
how ROS from NADPH oxidase activation produces glomerular injury remains unclear, which 
will be a major focus of the present study. 
 
1.2.2 Physiological and pathological role of NADPH oxidase in the kidney 
ROS play a very critical role in normal physiology in a variety of renal activities. It has 
been reported that in the kidney the major source of ROS production is through NADPH oxidase 
[78-79]. Many homeostatic processes of the kidney are affected by the activation of NADPH 
oxidase, including renal glucogenesis and transport, tubuloglomerular feedback, hemodynamics, 
and electrolyte transport [80]. Especially in the diabetic kidney, NADPH oxidase regulates 
proximal tubular cell glucose balance as well as the transport of glucose through sodium/glucose 
cotransporters [81-82].  O2
•−
 increases tubuloglomerular feedback and, therefore, NADPH 
oxidase also helps control the hemodynamic response in situations of high salt [83]. Along the 
nephron, NADPH oxidase has been demonstrated to be important for control of proximal tubular 
Na
+
/K
+
-ATPase activity, Na
+
/K
+
/2Cl
–
 cotransporters, and epithelial sodium channel (ENaC) 
activity [84-86], all suggesting regulation of tubular ion transport by NADPH oxidase. 
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However, as with any organ, the kidney is vulnerable when exposed to continuous, 
excessive levels of oxidative stress [87-88]. Diabetic mice have increased gp91
phox
/Nox2 
expression in the renal cortex, where Nox2 downregulation proved protective from diabetes-
induced oxidative stress, glucose intolerance, and renal fibrosis [89]. O2
•−
 production has been 
demonstrated to impair endothelial function and perhaps lead to increased arterial responsiveness 
to vasoconstricting stimuli [90-91]. Previous studies have demonstrated NADPH oxidase-derived 
O2
•−
 production to also regulate renal medullary blood flow, where persistently increased 
oxidative stress may contribute to the development of hypertension [92]. During hHcys, our 
laboratory has demonstrated the importance of NADPH oxidase in the pathogenesis of hHcys-
induced glomerular sclerosis by showing that inhibition or deletion of NADPH oxidase and its 
subunits, in particular, gp91
phox
, can attenuate glomerular damage and restore normal renal 
function [48].  Similarly, antioxidants have been shown to ameliorate Hcys-induced toxicity 
[64]. The current study seeks to further explore the mechanisms by which elevated Hcys and its 
activation of NADPH oxidase lead to glomerular dysfunction and the pathological progression to 
ESRD via NLRP3 inflammasomes, an intracellular inflammatory machinery. 
 
1.3 The NLRP3 inflammasome 
The Nod-like receptor protein 3 (NLRP3) inflammasome, found to be a key mediator of the 
innate immune system in response to a host of initiating factors, has been extensively 
demonstrated to be activated in response to a wide range of danger signals derived from disease 
and infection [93-97]. Oligomerization of the NLRP3 protein, the adaptor molecule apoptosis-
associated speck-like protein containing a CARD (caspase recruitment domain) (ASC), and the 
cysteine protease caspase-1 forms this cytosolic multiprotein complex, causing the maturation of 
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pro-inflammatory cytokines IL-1β and IL-18. It is assumed that this inflammasome activation 
and extracellular secretion of inflammatory cytokines sense diverse danger signals and instigate 
the innate inflammatory response, in particular, the sterile inflammatory response during chronic 
degenerative diseases [98-99]. More recently, NLRP3 inflammasome activation has been 
reported to trigger many other cell injury responses far beyond inflammation [100]. It has been 
assumed that the inflammatory and non-inflammatory actions produced by activation of NLRP3 
inflammasomes together induce cell or tissue degenerative injuries during many chronic diseases 
such as atherosclerosis, Alzheimer‟s diseases, cancer, metabolic disorders and gout [101]. Recent 
studies in our laboratory have found that the activation of these inflammasomes during hHcys 
turns on local inflammatory response in glomeruli, inducing kidney senescence and progressive 
degenerative glomerular dysfunction and sclerosis, where active caspase-1 promotes maturation 
of IL-1β to induce decreases in nephrin expression in podocytes [49].  
 
1.3.1 Types of inflammasomes 
The pro-inflammatory cytokine IL-1β, one of most powerful inflammatory mediators, is the 
most studied cytokine due to its key role in the inflammatory process. Jurg Tschopp and his 
research group identified the inflammasome as the molecular platform required for the activation 
of caspase-1, previously known as interleukin converting enzyme (ICE), which is responsible for 
the maturation of IL-1β from its precursor form [102]. There are various types of inflammasomes 
centered around different members of the Nod-like receptor (NLR) family, and although 23 NLR 
genes have been identified to date, only a few form oligomeric complexes and result in 
posttranslational activation of caspases [103]. Although caspases are generally thought to be pro-
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apoptotic, a subclass of inflammatory caspases is responsible for the maturation of inactive 
cytokine precursors like IL-1β and IL-18 [104]. 
 
 The major caspase-processing inflammasomes currently found throughout the literature 
include the NLRP1, NLRC4, AIM2, and NLRP3 inflammasomes. The NLRP1 inflammasome, 
shown to minimally require only NLRP1 and caspase-1 for its activation, has been demonstrated 
to be sensitive to bacterial cell wall component muramyl dipeptide (MDP) as well as Bacillus 
anthracis lethal toxin [105-106]. However, it was also shown that the addition of the adaptor 
protein ASC resulted in a more robust activation of the NLRP1 inflammasome. The NLRC4 
inflammasome is most associated with caspase-1 activation and IL-1β in response to various 
gram-negative bacteria. As with the NLRP1 inflammasome, NLRC4 can also directly interact 
with the CARD domain of caspase-1, and it has been hypothesized that NLRC4 activates 
caspase-1 upon sensing the presence of bacteria-specific and conserved proteins: flagellin, rod, 
and needle [107-109]. AIM2 inflammasomes become activated by preferentially binding to 
cytosolic double-stranded DNA, where ASC then becomes recruited to AIM2, leading to the 
proteolytic cleavage of caspase-1 [110]. 
 
 However, because of its important role in sterile inflammation, the most widely studied 
member of the NLR family is the NLRP3 inflammasome. The NLRP3 inflammasome responds 
to a very diverse range of activators, including those of microbial origin, endogenous danger 
signals, and exogenous non-microbial stimuli. It has become of great scientific interest in not 
only trying to identify activators of the NLRP3 inflammasome, but also importantly trying to 
understand how such a broad range of stimuli can activate the same molecular platform [111]. 
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1.3.2 Exogenous and endogenous NLRP3 inflammasome activators 
Many studies have provided evidence of NLRP3 inflammasome activation in response to a 
whole host of various exogenous danger signals and microbes, including the influenza virus, 
adenoviruses, Staphylococcus aureus, E. coli, Neisseria gonorrhoe, and Candida albicans [112-
117]. Although the ability of the toxins from many of these microbes to form membrane pores is 
linked to an ability to activate NLRP3, it still remains unknown whether a single or a 
combination of pathogen-associated molecular patterns (PAMPs) is directly responsible for 
inflammasome activation. Another group of NLRP3 stimulators are the non-microbial 
phagocytosed materials, where monosodium urate crystal accumulation associated with gout was 
one of the first inflammatory diseases linked to the activation of NLRP3 [118]. In a similar 
manner, silica, asbestos, and aluminum salts have also been shown to trigger caspase-1 cleavage 
and IL-1β production via NLRP3 activation [119-120]. 
 
The activation of NLRP3 inflammasomes to a very wide range of endogenous danger 
signals is what makes NLRP3 unique among all other inflammasomes. Excessive levels of ATP 
was described as one of the first endogenous damage-associated molecular patterns (DAMPs) to 
induce NLRP3 inflammasome formation and activation, a mechanism involving high 
concentrations of extracellular ATP binding to the purinergic P2X7 receptor [121]. The 
aggregation of endogenous peptides like amyloid-β are also sensed by NLRP3 [122], leading to 
the production of pro-inflammatory cytokines, which explains the elevation of IL-1β detected in 
the brains of patients with Alzheimer‟s disease [123]. Cholesterol crystals are known to cause 
phagolysosomal damage, and have been recently shown to lead to the early activation of NLRP3 
and the promotion of a pro-atherosclerotic phenotype [124], while endogenous danger signal of 
 15 
trauma, hyaluronan, also triggers chemokine release in affected tissues through NLRP3 [125]. 
Finally, damage to pancreatic islet cells by hyperglycemia caused NLRP3 inflammasome 
activation, ultimately developing to glucose intolerance and insulin resistance in a murine model 
of diabetes [126]. We have since demonstrated that the elevated levels of the amino acid Hcys 
also cause NLRP3 inflammasome formation and activation, leading to podocyte injury and 
eventually glomerular sclerosis [49]. Inhibition of NLRP3 via ASC shRNA or the caspase-1 
inhibitor, WEHD, prevented Hcys-induced detrimental effects on glomerular structure and 
dysfunction, signifying a critical role for NLRP3 in the pathogenesis of ESRD related to hHcys 
[49]. 
 
1.3.3 NLRP3 inflammasomes in disease 
Deficiencies in this multiprotein complex have been associated with autoimmune disorders 
such as familial Mediterranean fever and Muckle-Wells syndrome, but aberrant NLRP3 
inflammasome activation has extended to many traditionally considered non-inflammatory 
disorders including diabetes, obesity, silicosis, liver toxicity, and kidney diseases [118, 120, 127-
130]. Here we will focus on the role of NLRP3 in metabolic disorders. 
 
Demonstrated in clinical trials, levels of circulating IL-1β are predictive of type 2 diabetes 
[131], and treatment with IL-1β antagonist anakinra demonstrated protective effects in these 
diabetic patients [132]. NLRP3
−/−
 mice as well as adipocytes isolated from NLRP3
−/−
 mice 
exhibited marked improvement in glucose tolerance and insulin, with reduced IL-1β production 
[133]. Most interestingly, weight loss in obese patients with type 2 diabetes resulted in a 
reduction of NLRP3 expression and activity in adipose tissue and improved glucose handling 
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[134], altogether suggesting an important role for NLRP3 in the pathogenesis of type 2 diabetes 
associated with obesity. Highly associated with obesity and diabetes, these patients are also at 
risk for cardiovascular disease (CVD). Recent studies have defined the potential benefit of 
caspase-1 inhibition as an intervention for myocardial infarction and ischemia [135-136]. NLRP3 
inflammasome activation occurs mainly in cardiac fibroblasts after myocardial 
ischemia/reperfusion injury, where ASC
−/−
 protects mice from phagocytic infiltration, 
myocardial fibrosis and dysfunction, and enlarged infarct size [137]. 
 
NLRP3
−/−
 has also been shown to protect mice from both renal ischemic acute tubular 
necrosis as well as the progression of chronic kidney disease (CKD) in the unilateral ureteral 
obstruction model [138-139]. NLRP3 mRNA levels correlated with renal function in CKD 
patients, and IL-1β and IL-18 levels are increased in both animal models and patients with CKD 
[139-140]. Thus, these studies strongly support a crucial role for NLRP3 inflammasome 
involvement in the progression of acute kidney injury and CKD. Glomerular IL-1β mRNA is 
enhanced after the first day of the mouse model of streptozotocin-induced diabetic 
glomerulosclerosis [141]. With podocytes being a major site of IL-1β synthesis [142], we further 
demonstrated that hHcys-induced glomerular injury and IL-1β production occurs in an NLRP3-
dependent mechanism [49]. 
 
1.4 Regulation of NLRP3 inflammasome activation 
Despite rapid and extensive efforts in identifying various agents that stimulate the NLRP3 
inflammasome, the underlying mechanisms by which these diverse danger signals activate the 
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same molecular machinery remain poorly understood. This next section will review the current 
status of this controversial area. 
 
1.4.1 Primary models of NLRP3 inflammasome activation 
The activation of NLRP3 inflammasomes has been implicated in a growing number of 
diverse pathological conditions, ranging from bacterial infections to cardiovascular dysfunction 
and metabolic syndrome [124, 143-145]. Despite the plethora of studies demonstrating the 
widespread prevalence of NLRP3 activation in disease, it remains poorly understood how this 
unique molecular machinery is activated in response to a very diverse range of stimuli. 
Particularly in phagocytes such as macrophages, it is known that NLRP3 inflammasome 
activation requires two signals – a „priming‟ transcriptional step that involves TLR/NF-κB 
signaling, followed by post-translational regulation responsible for the oligomerization of the 
inflammasome components and the maturation of pro-inflammatory cytokine IL-1β [146-147]. 
In some other cells like endothelial cells and podocytes, such a two signal pattern may not be 
needed, where a constitutive or basal expression of pro-IL-1 and other associated molecules may 
be adequate to form and activate NLRP3 inflammasomes, albeit to a lesser extent than those in 
phagocytes, but sufficient enough to produce pathological changes, in particular, in chronic 
degenerative disease [142]. Whether or not its activation needs priming, NLRP3 inflammasomes 
are usually triggered through three major signaling pathways, stimulated either separately or in 
combination. In this regard, K
+
 efflux and low intracellular K
+
 concentration caused by 
activation of the P2X7 purinergic receptor in response to ATP is considered as an important 
signaling pathway to activate NLRP3 inflammasomes [115, 148]. ATP has also been 
demonstrated to cause transient pore formation through pannexin-1, allowing NLRP3 stimulators 
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to cross the plasma membrane and directly activate inflammasome assembly [121]. Another 
activating mechanism of NLRP3 inflammasomes is related to the actions of lysosomal enzymes 
in response to asbestos, silica, monosodium urate (MSU) crystals, and other stimulations that are 
too large to cross the membrane and instead are taken up into the cell via phagocytosis. When 
frustrated or incomplete phagocytosis occurs, lysosomal rupture or permeability changes release 
cathepsin B, a lysosomal enzyme that activates NLRP3 inflammasomes [120]. In addition, 
reactive oxygen species (ROS) produced by many known activators of NLRP3 inflammasomes 
are also shown to be an critical mechanism triggering NLRP3 inflammasome formation and 
activation in response to many exogenous stimuli as well as endogenously produced or secreted 
molecules from damaged cells such as DAMPs [149]. It has been demonstrated that the crystal 
structure of NLRP3 has a highly conserved disulfide bond connecting the PYD domain and the 
nucleotide-binding site domain, which is highly sensitive to or regulated by altered redox states 
[150]. 
 
1.4.2 ROS and its role in NLRP3 inflammasome activation 
Due to the leucine-rich repeats (LRR) found in the C-terminus of NLRP3, it was originally 
hypothesized to act as a cytosolic receptor and directly bind to a ligand. However, this 
hypothesis was neglected after the discovery of many diverse stimuli that were all found to 
activate NLRP3, and it became much more accepted that NLRP3 sensed some molecular 
intermediate generated by these broad activators. The generation of ROS was one of the first 
intermediates discovered to be common to ATP, MSU, asbestos, and silica-induced NLRP3 
activation [120]. Since then, there have been many conflicting reports regarding the role of ROS 
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in this process, creating much controversy in trying to understand the regulation of NLRP3 
inflammasome activation. 
 
Some of the first studies reported the importance of NADPH oxidase-derived ROS in 
activating NLRP3 in response to ATP, asbestos, and silica [120, 151-152]. This has since been 
extended to more recent reports, where NADPH oxidase inhibition via diphenylene iodonium 
(DPI) or more specifically through gp91
phox
 blockade, can prevent free fatty acid, TNFα, and 
atheroprone oscillatory flow-induced NLRP3 inflammasome activation [153-155]. It has been 
disputed, however, that ROS are not involved in the activation of NLRP3 inflammasomes, but 
instead are derived from Toll-like receptors (TLRs) and contribute to the priming mechanism 
responsible for the transcriptional upregulation of NLRP3 and pro-IL-1β [156]. Additionally, 
macrophages isolated from gp91
phox−/−
 mice or patients with chronic granulomatous disease 
(CGD) and deficient NADPH oxidase display normal inflammasome function when challenged 
with NLRP3 agonists [119, 157]. Caspase-1 activation and IL-1β secretion in response to cyclic 
stretch was undisturbed in murine alveolar macrophages, even in those isolated from gp91
phox−/−
 
mice, demonstrating the dispensability of NADPH oxidase to NLRP3 activation in this particular 
mechanism [158]. Alternatively, there is an emerging role for mitochondrial ROS (mtROS) in 
the mechanism of NLRP3 inflammasome activation [159-160]. The same study by Wu et al 
revealed that mtROS inhibition by mitochondrial antioxidant SS-13 prevented cyclic stretch-
induced IL-1β. These greatly varying effects between ROS of NADPH oxidase or mitochondrial 
origin suggest that the mechanism of NLRP3 activation may be a very cell and stimuli-specific 
phenomenon. 
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While there is a plethora of evidence supporting ROS activation of NLRP3 
inflammasomes, the exact mechanisms by which NLRP3 senses these changes in oxidative stress 
are still largely unknown. In this regard, the canonical work done by Zhou et al provided strong 
evidence of thioredoxin-interacting protein (TXNIP) as a binding partner to NLRP3, where 
association between these two proteins was necessary for downstream inflammasome activation 
[126]. TXNIP, the negative regulator of the antioxidant thioredoxin (TRX), may time-
dependently dissociate from TRX to bind with NLRP3 leading to inflammasome formation and 
activation. This study also seeks to determine the involvement of TXNIP as a potential mediator 
between hHcys-induced oxidative stress and consequent NLRP3 inflammasome activation. 
 
1.5 Aims of the study 
The hypothesis to be tested in the present study states that: NADPH oxidase redox 
signaling mediates inflammasome activation in podocytes and glomerular injury during hHcys, 
ultimately resulting in glomerular sclerosis and ESRD. 
 
The specific aims are: 
1. To determine whether the in vitro formation and activation of NLRP3 inflammasomes by 
Hcys are associated with NADPH oxidase-mediated redox signaling in mouse podocytes 
and to explore the mechanisms mediating the action of NADPH oxidase-derived ROS on 
this inflammasome activation, including the potential involvement of specific ROS and 
TXNIP. 
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2. To determine whether in vivo hHcys-induced activation of NLRP3 inflammasomes and 
associated glomerular injury are blocked by selective inhibition of local NADPH oxidase 
activity or by knocking out the gp91
phox
 gene in mice. 
3. To determine whether in vivo activation of NADPH oxidase by overexpression of Vav2 
gene, an endogenous NADPH oxidase activator, enhances the inflammasome formation 
and glomerular injury in glomeruli of hyperhomocysteinemic mice. 
 
The overall hypothesis and the specific aims of this project are schematically represented in 
Figure 2. 
 
Figure 2. The working hypothesis. Through its inhibition both in vitro and in vivo, Aim 1 
and 2 will explore the role of NADPH oxidase in Hcys-induced NLRP3 inflammasome 
activation. These aims will include further understanding which ROS are responsible for 
NLRP3 activation as well as determine the potential role of TXNIP in this mechanism. Aim 3 
will further substantiate the role of NADPH oxidase by observing the effects of its 
overexpression of its endogenous activator and determining if that is sufficient to activate 
NLRP3 inflammasomes. 
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CHAPTER TWO 
GENERAL METHODS 
 
2.1 Culture of mouse podocytes 
A conditionally immortalized mouse podocyte cell line, graciously provided by Dr. Paul E. 
Klotman (Division of Nephrology, Department of Medicine, Mount Sinai School of Medicine, 
New York, USA), was constructed with a temperature-sensitive variant of the simian virus 
(SV40) containing a large T antigen (tsA58) inducible by interferon-γ at 33°C, allowing for 
cellular proliferation. These cells were cultured and maintained on collagen-coated flasks in 
RPMI 1640 medium supplemented with 10% fetal bovine serum, 10 U/ml recombinant mouse 
interferon-γ, 100 U/ml penicillin and 100 mg/ml streptomycin.  The podocytes were then 
passaged and allowed to differentiate to a mature cell type at 37°C for two weeks without 
interferon-γ before use in experiments. 
 
2.1.1 In vitro podocyte treatments 
Podocytes were treated with L-Hcys, which is considered to be the pathogenic form of 
Hcys, at a concentration of 40 μM for 24 hours, a dose and treatment time chosen based on 
previous studies [49]. Pharmacological NADPH oxidase inhibitors apocynin (100 μM), 
diphenylene iodonium (10 μM), and gp91ds-tat peptide (5 μM) were added to the cells 1 hour 
prior to Hcys treatment. ROS scavengers were used at the following doses: TEMPOL (100 μM), 
catalase (50 U/ml), tetramethylthiourea (TMTU, 100 μM), manganese (III) tetrakis (1-methyl-4-
pyridyl) porphyrin (MnTMPyP, 25 μM), polyethylene glycol-superoxide dismutase (PEG-SOD, 
 23 
50 U/ml), and ebselen (10 μM). The calcium channel blocker verapamil, which has been 
demonstrated to be a potent inhibitor of TXNIP, was used at a dose of 50 μM. 
 
2.1.2 siRNA transfection 
ASC and gp91
phox
 small interfering RNAs (siRNA) were purchased from Qiagen (Valencia, CA), 
while TXNIP siRNA was purchased from Life Technologies (Grand Island, NY). A 
nonsilencing, double-stranded RNA (Qiagen) was used as a negative control.  Briefly, podocytes 
were incubated with the serum-free medium for 15 minutes prior to ASC, gp91
phox
, TXNIP, or 
scrambled siRNA transfection using the siLentFect Lipid Reagent (Bio-Rad, Hercules, CA) 
according to the manufacturer‟s instructions.  After 18 hours of incubation at 37°C, the medium 
was changed, and cells were treated with 40 μM Hcys for 24 hours. 
 
2.1.3 Nucleofection 
Podocytes were transfected with a scrambled or Vav2 shRNA, or a constitutively active form of 
Vav2 (oncoVav2) plasmid directly to the nucleus via nucleofector technology developed by 
Lonza (Basel, Switzerland). This dominant active oncoVav2 plasmid containing an N-terminal 
truncation was a generous gift from Dr. Keith Burridge from the University of North Carolina at 
Chapel Hill [161]. The nucleofector technology involves the temporary creation of small pores in 
the membrane through electrical impulses together with cell-specific solutions to deliver 
substrates through the cytoplasm and into the nuclear membrane. Podocytes were trypsinized, 
counted, and 1 x 10
6
 cells were gently centrifuged at 90xg for 10 min at RT. Cells were 
resuspended in SF Cell Line nucleofector solution containing 2 μg plasmid DNA and then 
transferred into a certified cuvette. The cuvette was placed into the nucleofector system and 
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subject to cell-type specific program CM-137, chosen based on optimization experiments. 
Nucleofected cells were resuspended with pre-warmed medium and transferred to culture plates 
for use in experiments. 
 
2.2 Mouse model of hyperhomocysteinemia 
For all animal studies, eight-week old male C57BL/6J mice (Jackson Laboratories, Bar 
Harbor, ME, USA) were uninephrectomized to accelerate renal injury, as described previously 
[162].  After allowing a week for recovery after surgery, mice were fed either a normal diet or a 
folate-free (FF) diet for 4 weeks to induce hHcys [48].  Folates are a cofactor required for the 
breakdown of Hcys, and restricting folate consumption in the diet prevents the remethylation of 
Hcys back to methionine, causing elevated levels of plasma Hcys [38, 163]. After 4 weeks of 
treatment, all mice were placed in metabolic cages and urine samples were collected for 24 hours 
before collecting blood samples, sacrificing, and harvesting tissues for analysis. The Institutional 
Animal Care and Use Committee of Virginia Commonwealth University approved all protocols. 
 
2.2.1 In vivo mouse treatments 
For in vivo NADPH oxidase inhibition studies, gp91
phox−/−
 mice (Jackson Laboratories, Bar 
Harbor, ME, USA) as well as gp91
phox+/+
 mice that were injected intraperitoneally with gp91ds-
tat or scrambled gp91ds-tat at a dose of 5 mg/kg every day were used [164].  Developed by 
Pagano and his research group, this custom gp91ds-tat peptide constructed with a tat sequence 
(first 9 amino acids) to enable cell membrane penetration and inhibition of NADPH oxidase, was 
synthesized by RS Synthesis (Louisville, KY) with the following amino acid sequence: 
YGRKKRRQRRR-CSTRIRRQL [165]. 
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For in vivo ROS scavenging studies, mice received vehicle, 4-Hydroxy-2,2,6,6-
tetramethylpiperidine-1-oxyl (TEMPOL), or catalase treatment and were fed either a normal diet 
or a FF diet for 4 weeks to induce hHcys. 3 mM TEMPOL (~100 mg/kg/day, Sigma, St. Louis, 
MO) was administered to the mice through the drinking water, while catalase (Sigma) was 
injected intraperitoneally at a dose of 5 kU/kg/day [166-167].  
 
For in vivo TXNIP inhibition studies, one group of mice received plasmids encoding either 
the reporter gene luciferase or TXNIP short hairpin RNA (shRNA) by ultrasound-microbubble 
transfection. Another group of mice received verapamil in the drinking water (1 mg/ml), 
equating to a dose of approximately 100 mg/kg/day [168].  
 
For in vivo Vav2 overexpression and inhibition studies, mice received either Vav2 shRNA 
or constitutively active variant oncoVav2 via ultrasound-microbubble transfection. Following 
transfection, mice were maintained on either the normal or FF diet for 4 weeks. All of these 
treatment paradigms can be found in Figure 3. 
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Treatment 
Group A 
1 2 3 4 5 6 
ND + − + − + − 
FF − + − + − + 
gp91
phox−/−
 − − + + − − 
gp91ds-tat 
(5 /mg/kg/day) 
− − − − + + 
       
Treatment 
Group B 
1 2 3 4 5 6 
ND + − + − + − 
FF − + − + − + 
TEMPOL 
(100 mg/kg/day) 
− − + + − − 
Catalase 
(5000 U/kg/day) 
− − − − + + 
       
Treatment 
Group C 
1 2 3 4 5 6 
ND + − + − + − 
FF − + − + − + 
TXNIP shRNA − − + + − − 
Verapamil 
(100 mg/kg/day) 
− − − − + + 
       
Treatment 
Group D 
1 2 3 4 5 6 
ND + − + − + − 
FF − + − + − + 
Vav2 shRNA − − + + − − 
OncoVav2 − − − − + + 
 
    Figure 3. Different mouse treatment groups used in the present study. 
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2.2.2 Mouse genotyping 
Each mouse used in the in vivo NADPH oxidase inhibition studies was genotyped for the 
gp91
phox
 gene to confirm its deletion prior to use in experiments. Briefly, genomic DNA 
extracted from the tail was subjected to PCR amplification using taq DNA polymerase 
(Invitrogen, Inc., Grand Island, NY). Using a Bio-Rad iCycler, PCR was performed using a 
validated protocol provided by Jackson Laboratories: denaturing the DNA at 94°C for 3 min, 
followed by a first round of 12 cycles: 94°C for 20 sec, 64°C for 30 sec (-0.5°C per cycle), 72°C 
for 35 sec, and then a second round of 25 cycles: 94°C for 20 sec, 58°C for 30 sec, 72°C for 35 
sec, and a final extension step at 72°C for 2 min. The following gp91phox-specific primers were 
provided by Jackson Laboratory and used for genotyping: oIMR0517 (AAG AGA AAC TCC 
TCT GCT GTG AA), oIMR0518 (CGC ACT GGA ACC CCT GAG AAA GG), and oIMR0519 
(GTT CTA ATT CCA TCA GAA GCT TAT CG). The PCR products were separated by gel 
electrophoresis on a 3% agarose gel, visualized by ethidium bromide fluorescence, and compared 
to a 100 bp DNA ladder (New England Biosystems, Ipswich, MA). 
 
2.2.3 Ultrasound-microbubble transfection and in vivo imaging 
After allowing one week for recovery from uninephrectomy surgery, a preparation of 
plasmid encoding either TXNIP shRNA, oncoVav2, Vav2 shRNA or the reporter gene luciferase 
was mixed with cationically charged Optison microbubbles (GE Healthcare, Piscataway, NJ), 
then injected into the femoral artery and locally transfected to the kidney by sonoporation with a 
continuous wave output of 1 MHz at 10% power output at 30 sec intervals for a total of 6 min. 
To daily monitor the efficiency of gene expression, mice were anesthetized with ketamine (100 
mg/kg IP) and xylazine (10 mg/kg IP), and an aqueous solution of luciferin (150 mg/kg IP) was 
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injected 5 minutes before imaging, as described previously [49]. The anesthetized mice were 
imaged using the Xenogen IVIS200 in vivo imaging system (Perkin Elmer, Waltham, MA). 
Photons emitted from luciferase-expressing cells and transmitted through tissue layers were 
quantified over a defined period of time ranging up to 5 minutes using the software program 
Living Image (Xenogen) as an overlay on an Igor program (Wavemetrics). If transfection was 
not detected by in vivo imaging, the mice were sacrificed and experiments terminated due to 
unsuccessful transgene expression. 
 
2.3 Preparation of cell and tissue homogenates 
Cell homogenates were freshly prepared by washing cultured cells three times with ice-
cold PBS, followed by scraping the cells in ice-cold sucrose buffer (20 mM Tris-Hcl, 250 mM 
sucrose, pH 7.2) and transferring to a microcentrifuge tube pre-chilled on ice. Renal cortical 
tissue lysate was prepared by homogenizing the tissue in ice-cold sucrose buffer using a 
motorized microcentrifuge conical pestle. These homogenates from cells and tissues then 
underwent sonication using a handheld sonicator for 10 pulses on ice. This was repeated until all 
samples underwent sonication for a total of 3 times. Samples were incubated on ice for 30 
minutes prior to centrifugation at 7,500 x g for 15 minutes at 4° C to remove cellular debris, and 
the supernatant was transferred to a new, pre-chilled microcentrifuge tube for use in downstream 
assays. 
 
2.4 Microsome preparation 
Podocyte lysate was subject to centrifugation at 1,000g for 10 minutes at 4° to remove the 
nuclear fraction.  The collected supernatant was then centrifuged at 10,000g for 20 minutes at 4° 
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to remove the granular fraction.  The resulting supernatant was assayed for protein concentration 
to normalize protein loading across all samples, and subject to a final centrifugation at 100,000g 
for 90 minutes at 4° to separate the microsomes (pellet) and cytosolic fraction (supernatant).  The 
isolated pellet was then immediately assayed for O2
•−
 production using electromagnetic spin 
resonance analysis as described in the following sections. 
 
2.5 Western blot analysis 
Cell or tissue homogenates were loaded in equal protein concentration (10-20 μg) and run 
at 120V for 1.5 hrs using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE). The proteins were transferred from the gel onto polyvinylidene fluoride nitrocellulose 
membranes for 1 hr at 100V. After blocking the membranes for 1 hr with 5% non-fat dry milk in 
Tris-buffered saline with 0.1% Tween 20 (TBS-T), the membrane was probed with rabbit anti-
ASC (1:1000, Enzo, Farmingdale, NY), rabbit anti-NLRP3 (1:500, Abcam, Cambridge, MA) or 
mouse anti-TXNIP (1:1000, MBL, Woburn, MA) overnight at 4°C, followed by incubation with 
the appropriate horseradish peroxidase-labeled IgG (1:5000) at RT for 1 hr. The bands were 
detected by chemiluminescence and visualized on Kodak Omat X-ray films, and band density 
was analyzed by ImageJ software (NIH, Bethesda, MD).  
 
2.6 Confocal microscopy and immunofluorescence of frozen tissue and cell slides 
Indirect immunofluorescent staining was used to observe the colocalization of 
inflammasome and podocyte marker proteins in both cultured cells as well as frozen mouse 
kidney sections. Podocytes seeded in 8-well chambers were fixed in 4% paraformaldehyde 
(PFA), washed with phosphate-buffered saline (PBS), and blocked with 1% bovine serum 
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albumin (BSA) in PBS before being incubated in primary antibodies (1:100) overnight at 4°C. 
The primary goat anti-NLRP3 (Abcam, Cambridge, MA) antibody was used in combination with 
the following: rabbit anti-ASC (Santa Cruz, Dallas, TX), rabbit anti-caspase (Santa Cruz), or 
mouse anti-TXNIP (MBL, Woburn, MA). Frozen mouse kidney tissue slides were fixed in 
acetone, blocked with 3% donkey serum, then incubated with the same aforementioned primary 
antibodies (1:50) overnight at 4°C. Some coverslips with podocytes and frozen kidney sections 
were only stained for podocyte markers podocin (1:50; Sigma, St. Louis, MO) or desmin (1:50; 
BD Biosciences, San Jose, CA), or also in combination with goat anti-NLRP3 antibody. Double 
immunofluorescent staining was performed by Alexa-488 or Alexa-555-labeled secondary 
antibody (1:200 podocytes, 1:50 frozen kidney slides; Life Technologies, Grand Island, NY) 
incubation for 1 hr at room temperature. Slides were then washed, mounted, and observed using 
a confocal laser scanning microscope (Fluoview FV1000, Olympus, Japan) and tools in Image 
Pro Plus 6.0 software (Media Cybernetics, Bethesda, MD) was used to analyze colocalization, or 
the degree of overlap between the two wavelengths, which was expressed as the Pearson 
Correlation Coefficient. 
 
2.7 Size-exclusion chromatography 
As described in our previous studies [169-170], homogenates from either treated podocytes 
or renal cortical tissue was prepared using the following protein extraction buffer: 20 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid-KOH (pH 7.5), 10 mM KCl, 1.5 mM Na-EDTA, 
1 mM Na-EGTA, and 1x protease inhibitor cocktail (Roche Applied Science, Indianapolis, IN). 
Samples were centrifuged at 16,000g for 10 minutes at 4°C, the supernatant filtered through a 
0.45 μm centrifuge tube filter, and the protein concentration was measured. Samples were 
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normalized by loading 1 mg protein in less than 500 μl total volume onto a Superose 6 10/300 
GL Column using an ÄKTAprime plus fast-protein liquid chromatography (FPLC) system (GE 
Healthscience, Uppsala, Sweden). Fractions were collected (600 μl), protein precipitated using 
tricholoroacetic acid, and analyzed by Western blot as described above. 
 
2.8 Co-immunoprecipitation 
Renal cortical tissue was homogenized on ice in IP lysis buffer (30 mM Tris-HCl, 150 mM 
NaCl, 2 mM EDTA, 1% Triton X-100, 10% glycerol, 1x Protease Inhibitor) followed by brief 
pulses of hand sonication. After a 30 minute incubation on ice, the lysate was centrifuged and the 
supernatant precleared by incubation with Protein A/G PLUS-Agarose Beads (Santa Cruz, sc-
2003) in 4°. The precleared supernatant was incubated with 2 µg antibody against NLRP3 
(Abcam) for 4 hours on a rocker in 4°. Beads were added for an additional 1 hr, and then 
immunoprecipitates collected by centrifugation at 1,000g for 5 minutes and washed three times 
with IP lysis buffer with centrifugation after each wash. The pellet was resuspended in 2x sample 
buffer, boiled, and analyzed for NLRP3 and TXNIP protein expression by Western blot. 
 
2.9 Caspase-1 activity, IL-1β production, and VEGF measurements 
Caspase-1 activity was measured by a commercially available colorimetric assay 
(Biovision, Mountain View, CA), while IL-1β production and vascular endothelial growth 
factor-A (VEGF-A) secretion was measured in the supernatant of cultured podocytes using an 
enzyme-linked immunosorbent assay (R&D System, Minneapolis, MN) according to 
manufacturer‟s instructions. 
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2.10 Electron spin resonance spectrophotometry of O2
•−
 production 
Protein from cultured podocytes or renal cortical tissue was extracted using a sucrose 
buffer, and then prepared for analysis by resuspension in a modified Krebs-Hepes buffer 
containing deferoximine (100 μM; Sigma, St. Louis, MO, USA) and diethyldithiocarbamate (5 
μM; Sigma). To measure NADPH oxidase-dependent superoxide production, 1 mM NADPH 
substrate was added to 50 μg protein, and each sample was read twice on an ESR spectrometer 
and examined in the presence or absence of superoxide dismutase (SOD, 200 U/ml; Sigma). 1-
hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethylpyrrolidine (CMH, 1mM), a superoxide
 
specific 
spin trapping compound, was added to the sample before being loaded into a glass capillary, and 
analyzed in an ESR spectrometer for 10 minutes [171].  Results were obtained by taking the 
difference between the total CMH signal without SOD and the SOD-specific signal, and all 
values were expressed as the fold change from the control. 
 
2.11 RNA isolation and real time RT-PCR 
Total RNA was isolated from both podocytes and renal cortical tissue using the TRIzol 
reagent (Grand Island, NY), reverse transcribed to cDNA, and subject to PCR amplification 
according to the procedures described previously [172]. All primers were synthesized by Operon 
(Huntsville, AL) with the following sequences: Nox1, sense 5-AATGCCCAGGATCGAGGT, 
antisense 5-GATGGAAGCAAAGGGAGTGA-3; Nox2, sense 5-
TGGCACATCGATCCCTCACTGAAA-3, antisense 5-GGTCACTGCATCTAAGGCAACCT-
3; Nox4, sense 5-GAAGGGGTTAAACACCTCTGC-3, antisense 5-
ATGCTCTGCTTAAACACAATCCT-3; TXNIP, sense 5-CAGCCTACAGCAGGTGAGAAC-
3, antisense 5-CTCATCTCAGAGCTCGTCCG-3.  
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2.12 F-actin staining of podocytes 
To determine the role of NADPH oxidase and inflammasome activation in Hcys-induced 
cytoskeleton changes, podocytes were cultured in 8-well chambers. After washing with PBS, the 
cells were fixed in 4% PFA for 15 min at room temperature, permeabilized with 0.1% Triton X-
100, and blocked with 3% bovine serum albumin. F-actin was stained with rhodamine–phalloidin 
(Invitrogen, Carlsbad, CA) for 15 min at room temperature. After mounting, the slides were 
examined by a confocal laser scanning microscope (Fluoview FV1000, Olympus, Japan). Cells 
with distinct F-actin fibers were counted as described previously [173]. Scoring was obtained 
from 100 podocytes from each group on each slide. 
 
2.13 Immunohistochemistry 
Kidneys were embedded with paraffin and 5 μm sections were cut from the embedded 
blocks. After heat-induced antigen retrieval, CD43 staining of T cells and WT-1 staining of 
podocytes required citrate buffer antigen retrieval, while F4/80 staining of macrophages required 
Proteinase K antigen retrieval. After a 20 min wash with 3% H2O2 and 30 min blocking with 
serum, slides were incubated with primary antibodies diluted in phosphate-buffered saline (PBS) 
with 4% serum. Anti-CD43 (1:50; Santa Cruz Biotechnology, Santa Cruz, CA), anti-F4/80 (1:50; 
AbD Serotec, Raleigh, NC), and anti-WT-1 (1:50; Abcam, Cambridge, MA) antibodies were 
used in this study for detection of macrophages and T-cells. After incubation with each of these 
primary antibodies overnight, the sections were washed in PBS and incubated with biotinylated 
IgG (1:200) for 1 h and then with streptavidin-HRP for 30 min at room temperature. 50 μl of 
DAB was added to each kidney section and stained for 1 min. After washing, the slides were 
counterstained with hematoxylin for 5 min. The slides were then mounted and observed under a 
 34 
microscope, and photographs were taken at 100x magnification. All of the glomeruli in the 
cortical fields were counted and blindly used for analysis of each slide [174]. 
 
2.14 Chronic catheterization and arterial blood pressure measurement 
Mean arterial pressure (MAP) was measured for 3 days in mice involved with the TXNIP 
inhibition studies, including luciferase-transfected, TXNIPsh-transfected, or verapamil-
administered mice, to make sure there were no effects of diet or treatment on blood pressure. As 
we described previously [175-176], mice were anaesthetized by isoflurane inhalation, and a 
telemetry transmitter catheter implanted into the carotid artery. The transmitter was placed 
subcutaneously, allowing mice to be housed unrestrained, with the arterial blood pressure signal 
transmitted to a remote receiver (Data Sciences International, St. Paul, MN, USA). 
 
2.15 Urinary protein and albumin measurements 
Total urinary protein excretion was determined spectrophotometrically using the Bradford 
assay (Sigma) using a standard curve of BSA, and urinary albumin excretion was measured 
using a commercially available mouse albumin ELISA kit (Bethyl Laboratories, Montgomery, 
TX). 
 
2.16 Glomerular morphological examination 
Renal tissues were fixed with a 10% formalin solution, paraffin-embedded, and stained 
with periodic acid–Schiff (PAS). Renal morphology was observed using a light microscope, and 
glomerular sclerosis was assessed semiquantitatively and expressed as glomerular damage index 
(GDI) [177].  Fifty glomeruli per slide were counted and blindly scored as 0, 1, 2, 3, or 4, 
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according to 0, <25, 25–50, 51–75, or >75% sclerotic changes, respectively, across a longitudinal 
kidney section. The GDI for each mouse was calculated by the formula ((N1 ×1) + (N2 ×2) + 
(N3 ×3) + (N4 ×4))/n, where N1, N2, N3, and N4 represent the numbers of glomeruli exhibiting 
grades 1, 2, 3, and 4, respectively, and n is the total number of glomeruli scored. 
 
2.17 HPLC analysis of plasma Hcys 
Total plasma Hcys levels were measured by HPLC as previously described [178-179]. A 
100 µL plasma or standard solution mixed together with 10 µL of the internal standard 
thioglycolic acid (2.0 mmol/L) solution, was treated with 10 µL of 10% tri-n-butylphosphine 
(TBP) solution in dimethylformamide at 4°C for 30 minutes. In order to precipitate and remove 
proteins in the sample, 80 µL of ice-cold 10% trichloroacetic acid (TCA) in 1 mmol/L EDTA 
was added and followed with centrifugation. 100 µL of the resulting supernatant was transferred 
into the mixture of 20 µL of 1.55 mol/L sodium hydroxide, 250 µL of 0.125 mol/L borate buffer 
(pH 9.5), and 100 µL of 1.0 mg/mL 7-fluoro-2,1,3-benzoxadiazole-4-sulfonamide (ABD-F) 
solution, then incubated at 60°C for 30 minutes to achieve derivatization of thiols. HPLC was 
performed with a HP 1100 series instrument equipped with a binary pump, a vacuum degasser, a 
thermo stated column compartment, and an auto sampler (Agilent Technologies, Waldbronn, 
Germany). Separation was carried out at ambient temperature on a Supelco LC-18-DB (Supelco; 
150×4.6 mm i.d., 5 µm particle size) analytical column with a Supelcosil LC-18 guard column 
(Supelco; 20×4.6 mm i.d., 5 µm particle size). Fluorescence intensities were measured with a 
Hewlett-Packard Model 1046A fluorescence detector (excitation: 386 nm, emission: 515 nm), 
with a Hewlett-Packard 3392 integrator quantifying the peak area of the chromatographs. The 
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analytical column was eluted with 0.1 mol/L potassium dihydrogen phosphate buffer (pH 2.1) 
containing 6% acetonitrile (v/v) as the mobile phase with a flow rate of 2.0 mL/min. 
 
2.18 Statistical analysis 
All results were expressed as the arithmetic mean ± SEM; n represents the number of 
independent experiments. Data obtained from multiple animal or experimental groups were 
tested for significance using one- or two-way ANOVA, and a paired and unpaired Student‟s t-
test was used for two animal or experimental groups. A χ2 test was used to determine the 
significance of ratio and percentage data. Results with p<0.05 were considered statistically 
significant.  
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CHAPTER THREE 
NADPH oxidase-mediated triggering of inflammasome activation in mouse podocytes and 
glomeruli during hyperhomocysteinemia 
 
3.1 Rationale and Hypothesis 
As depicted in Figure 4 the present study hypothesized that NADPH oxidase-mediated 
redox signaling play an essential role in triggering hHcys-induced inflammasome activation 
within podocytes, thereby inducing glomerular inflammatory injury such as immune cell 
infiltration and consequently leading to glomerular sclerosis. To test this hypothesis, we first 
used cultured murine podocytes to examine whether inhibition of NADPH oxidase attenuates 
Hcys-induced NLRP3 inflammasome formation and activation and also addressed the functional 
relevance of this early inflammatory event. Using pharmacological inhibitors or mice lacking the 
gp91
phox
 gene, we also tested the in vivo role of NADPH oxidase activation in hHcys-induced 
NLRP3 inflammasome formation and activation, glomerular inflammatory pathology and 
glomerular sclerosis compared with wild-type littermates. 
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3.2 Results 
3.2.1 Attenuation of Hcys-induced NLRP3 inflammasome formation through inhibition 
of NADPH oxidase 
As shown in Figure 5A, confocal microscopic analysis demonstrated that Hcys induced the 
colocalization of inflammasome markers (NLRP3 with ASC and NLRP3 with caspase-1) in 
podocytes compared to untreated control cells. Pretreatment of podocytes with NADPH oxidase 
inhibitors DPI or gp91ds-tat peptide significantly abolished the Hcys-induced aggregation of 
NLRP3 with ASC and NLRP3 with caspase-1, suggesting blockade of inflammasome formation 
in these cells.  Furthermore, small interfering RNA against ASC and gp91
phox
 also blocked Hcys-
 
Figure 4. Representative schematic for Aims 1 and 2. Through the specific inhibition of 
gp91
phox
 both in vitro and in vivo, Aim 1 and 2 will explore the role of NADPH oxidase in 
Hcys-induced NLRP3 inflammasome activation.  
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induced inflammasome formation. The Pearson correlation coefficient was calculated for each of 
the groups using the colocalization analysis program in the Image Pro Plus 6.0 software and 
summarized in Figure 5B. In addition, co-immunoprecipitation experiments demonstrated that 
Hcys significantly increased the binding of NLRP3 and caspase-1 together with ASC compared 
to control cells, which is attenuated in the presence of apocynin and gp91ds-tat peptide (data not 
shown). Together, these results suggest that inhibition of NADPH oxidase or silencing ASC gene 
attenuates Hcys-induced inflammasome formation in podocytes.  
  Size-exclusion chromatography (SEC) was employed to further determine the role of 
NADPH oxidase in the process of Hcys-induced inflammasome complex formation. A 
representative chromatogram is shown in Figure 6A, illustrating the peaks produced from both a 
standard and typical protein sample when run and separated by the Sepharose 6 column. As 
depicted in Figure 6B, under control conditions the specific bands for NLRP3 and ASC were 
located in the low molecular weight fractions (18-22). Upon stimulation with Hcys for 24 hours, 
the NLRP3 and ASC bands markedly shifted to high molecular weight fractions (3-7), termed 
the inflammasome fractions due to complex formation. However, when NADPH oxidase was 
inhibited in podocytes by treatment with gp91ds-tat or DPI prior to the addition of Hcys, a clear 
decrease in inflammasome protein complex aggregation was observed in the high-molecular 
weight fractions. The intensity of these bands were quantified by ImageJ software and 
summarized in Figure 6C. 
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Figure 5.  NADPH oxidase inhibition attenuated inflammasome formation induced by 
hHcys in podocytes.  A.  Confocal images representing the colocalization of NLRP3 (green) 
with ASC (red) and NLRP3 (green) with caspase-1 (red) in podocytes.  B.  Summarized data 
showing the fold change of PCC for the colocalization of NLRP3 with ASC and NLRP3 with 
caspase-1. (n=6-7). Ctrl: Control; Vehl: Vehicle; gp91pep: gp91ds-tat; DPI: diphenylene 
iodonium; Scram: Scramble siRNA; ASCsi: ASC siRNA; gp91si: gp91
phox
 siRNA.  * P<0.05 
vs. Control; # P<0.05 vs. Hcys. 
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Figure 6.  Distribution of inflammasome components after size-exclusion 
chromatography of podocytes.  A.  Elution profile of proteins from both a standard and 
podocyte samples at an absorbance of 280 nm.  Molecular mass of the samples were 
determined by comparison to a gel filtration standard.  B.  Western blot analysis of FPLC 
protein fractions obtained from untreated, Hcys-treated, and gp91ds-tat-treated podocytes 
probed with anti-NLRP3 and ASC antibodies.  C.  Summarized data showing the band 
intensities measured from the inflammasome complex fractions (fractions 3-7) of NLRP3 and 
ASC (n=4-6). Ctrl: Control; Vehl: Vehicle; gp91pep: gp91ds-tat; DPI: diphenylene iodonium; 
gp91sh: gp91
phox
 shRNA, APO: apocynin. * P<0.05 vs. Control; # P<0.05 vs. Hcys. 
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3.2.2 Inhibition of NADPH oxidase blocked NLRP3 inflammasome functionality by 
suppressing caspase-1 activity and IL-1b secretion 
We further tested whether inhibition of NADPH oxidase also attenuates Hcys-induced 
caspase-1 activity and IL-1β production in podocytes. As shown in Figure 7A, the increase in 
caspase-1 activity caused by Hcys was markedly inhibited by the NADPH oxidase inhibitors 
apocynin, DPI, gp91ds-tat, and gp91
phox 
siRNA, implicating an important role for NADPH 
oxidase in inflammasome activation. ASC siRNA also produced a similar significant decrease in 
caspase-1 activity.  Figure 7B demonstrated that these decreases in caspase-1 activity also 
resulted in less IL-1β being converted from the pro-inflammatory cytokine form to the active 
form during the simultaneous treatment of Hcys with either NADPH oxidase or inflammasome 
inhibitors. 
 
3.2.3 Effect of NLRP3 inflammasome inhibition on Hcys-induced O2
•−
 production 
To determine whether NADPH oxidase-derived O2
•−
 plays a role in inflammasome 
activation, O2
•−
 levels were measured in podocytes pretreated with NADPH oxidase or 
inflammasome inhibitors in the presence of Hcys.  As expected, treatment of podocytes with 
DPI, gp91ds-tat, or gp91
phox
 siRNA produced a distinct decrease in O2
•−
 production when 
compared to Hcys alone (Figure 7C).  Additionally apocynin or gp91ds-tat peptide also 
significantly attenuated the Hcys-induced O2
•−
 production in the plasma membranes of podocytes 
(Figure 7D). However, ASC siRNA or caspase-1 inhibition could not prevent the Hcys-induced 
increase in O2
•−
. This suggests that NADPH oxidase activation by Hcys and subsequent 
production of O2
•−
 is upstream of inflammasome activation, given that inhibition of the 
inflammasome did not affect the levels of NADPH oxidase-derived O2
•−
. 
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Figure 7.  Effects of NADPH oxidase inhibition and ASC silencing on Hcys-induced 
caspase-1 activity, IL-1β secretion, and O2
•−
 production in podocytes.  A.  Caspase-1 
activity in groups treated with Hcys in the presence of various genetic and pharmacologic 
inhibitors of NADPH oxidase and the inflammasome (n=6).  B.  IL-1β production in 
podocytes treated with Hcys in the presence of various genetic and pharmacologic inhibitors 
of NADPH oxidase and the inflammasome (n=6). C.  Hcys-induced O2
•−
 production 
decreased with treatment of NADPH oxidase inhibitors, but not genetic or pharmacologic 
inhibitors of the inflammasome (n=5). D. Hcys induced superoxide production in microsomes 
isolated from cultured podocytes, which was prevented by pharmacological NADPH oxidase 
inhibitors APO and gp91pep (n=4-5). Ctrl: Control; Vehl: Vehicle; gp91pep: gp91ds-tat; DPI: 
diphenylene iodonium; Scram: Scramble siRNA; ASCsi: ASC siRNA; gp91si: gp91
phox
 
siRNA; APO: apocynin. * P<0.05 vs. Control; # P<0.05 vs. Hcys. 
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3.2.4 Inhibition of NADPH oxidase or NLRP3 inflammasomes attenuated Hcys-induced 
podocyte injury 
As shown in Figure 8A, immunofluorescent analysis demonstrated that Hcys stimulation 
increased desmin expression in podocytes compared to untreated cells. Prior treatment with 
gp91
phox
 siRNA, ASC siRNA, gp91ds-tat, apocynin, DPI, or caspase-1 inhibitor WEHD 
decreased this Hcys-induced desmin expression in podocytes. Another podocyte marker, 
podocin, was markedly reduced upon Hcys stimulation in podocytes, and prior treatment with 
the same inhibitors almost completely attenuated the decrease in podocin expression. Positive 
cells were counted and summarized in Figure 8B. These results signify the importance of both 
NADPH oxidase and inflammasome functionality in this injurious process of podocytes when 
exposed to Hcys.  Using rhodamine-phalloidin to stain F-actin, the control condition exhibited 
well-defined F-actin fibers which run along the longitudinal axis of these podocytes, and as 
demonstrated by the obvious lack of distinct fibers, Hcys resulted in a significant loss of these 
longitudinal fibers as they reorganize to the cell border.  Puromycin aminonucleoside (PAN), a 
classic and specific inducer typical used to cause podocyte injury [180], served as a positive 
control (Figure 8C). However, inhibition of NADPH oxidase or inflammasomes hindered the 
Hcys-induced decrease and rearrangement of F-actin.  These changes in F-actin staining were 
summarized in Figure 8D. 
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Figure 8. Amelioration of Hcys-induced podocyte dysfunction by NADPH oxidase and 
inflammasome inhibitors.  A. Immunofluorescence staining showed that inhibition of 
NADPH oxidase activation by gp91
phox
 siRNA, gp91ds-tat, apocynin and DPI, or 
inflammasome inhibition by ASC siRNA or WEHD rescued Hcys-induced expression of 
podocyte marker podocin (original magnification, x400). Inhibition of NADPH oxidase or 
inflammasome activation also resulted in suppressed expression of podocyte injury marker 
desmin. B. Summarized data shows the percentage of podocyte cells positive for podocin and 
desmin. C.  Microscopic images of F-actin by rhodamine-phalloidin staining (original 
magnification, x400).  PAN treatment served as a positive control. D. Summarized data from 
counting the cells with distinct, longitudinal F-actin fibers.  Scoring was determined from 100 
podocyte cells on each slide (n=5-6).  Ctrl: Control; Vehl: Vehicle; gp91pep: gp91ds-tat; DPI: 
diphenylene iodonium; Scram: Scramble siRNA; ASCsi: ASC siRNA; gp91si: gp91
phox
 
siRNA.  * P<0.05 vs. Control; # P<0.05 vs. Hcys. 
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3.2.5 gp91phox−/− and gp91ds-tat-treated mice had no hHcys-induced glomerular NLRP3 
inflammasome formation and activation 
To further confirm the role of NADPH activation in vivo in experimental hHcys mice, 
double fluorescent-immunostaining of kidney slides was performed. As shown in Figure 9A, 
under control condition NLRP3, ASC and caspase-1 were expressed at low levels within the 
glomeruli, and very few colocalizations of these inflammasome molecules could be detected by 
confocal microscopy. In gp91
phox+/+ 
mice, the colocalization of NLRP3 with ASC or caspase-1 
markedly increased in glomeruli of FF diet-fed hHcys mice. However, the increased 
colocalization of NLRP3 with ASC or caspase-1 was suppressed in glomeruli of 
hyperhomocysteinemic gp91
phox−/−
 and gp91ds-tat-treated mice. The summarized data were 
shown in Figures 9B and 9C. In addition, using podocin and desmin as podocyte markers we 
showed that hHcys-induced inflammasome activation in glomeruli was mostly located in 
podocytes, as demonstrated by the colocalization of podocin with NLRP3 or caspase-1 and 
desmin with NLRP3 or caspase-1. This colocalization was substantially blocked in 
hyperhomocysteinemic gp91
phox−/−
 mice and gp91ds-tat-treated mice (Figure 9A). The 
summarized data were shown in Figures 9D and 9E. 
Consistent with decreased aggregation of inflammasome components in the glomeruli, 
hHcys-enhanced caspase-1 activity and IL-1β production were markedly attenuated in glomeruli 
of gp91
phox−/−
 and gp91ds-tat-treated mice (Figures 10A and 10B). In addition, hHcys-induced 
glomerular superoxide production was significantly attenuated in gp91ds-tat-treated and 
gp91
phox−/−
 mice compared to their wild-type littermates (Figure 10C). The plasma Hcys 
concentration was similar in gp91
phox+/+
, gp91
phox−/−
 and gp91ds-tat-treated mice on the normal 
diet. However, the FF diet significantly increased the plasma Hcys concentration in all three 
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groups compared to normal diet fed mice (gp91
phox+/+
 mice: 12.6 ± 2.0 versus 4.1 ± 0.41 μM for 
control; gp91
phox−/−
 mice: 13.0 ± 1.6 versus 4.0 ± 0.8 μM for control; gp91ds-tat mice: 11.6 ± 1.0 
versus 5.1 ± 0.41 μM for control). 
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Figure 9.  Attenuation of Hcys-induced inflammasome activation in the glomeruli of 
gp91
phox−/− 
and gp91ds-tat-treated mice on a FF diet.  A.  Colocalization of NLRP3 (green) 
with ASC (red), NLRP3 (green) with caspase-1 (red),  and NLRP3 (green) with podocyte 
marker podocin (red) in the mouse glomeruli of gp91
phox+/+
, gp91ds-tat, and gp91
phox−/−
 mice 
fed a normal or FF diet.  B and C. Summarized data showing the correlation coefficient 
between NLRP3 with ASC and NLRP3 with caspase-1 (n=7). D and E. Summarized data 
showing the correlation coefficient between NLRP3 with podocin and caspase-1 with podocin 
(n=4-5). *P<0.05 vs. gp91
phox+/+
 on Normal Diet; # P<0.05 vs. gp91
phox+/+
 on FF Diet. 
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Figure 10. In vivo effect of NADPH oxidase inhibition on Hcys-induced caspase-1 
activity, IL-1β secretion, and O2
•−
 production.  A.  Caspase-1 activity in gp91
phox+/+
, 
gp91ds-tat, and gp91
phox−/−
 mice with hHcys induced by the FF diet (n=6).  B. IL-1β 
production induced by hHcys was inhibited in both the mice treated with gp91ds-tat and in 
gp91
phox−/−
 mice (n=6). C.  Hcys-induced superoxide production was attenuated in the gp91ds-
tat and gp91
phox−/−
 groups (n=5). * P<0.05 vs. gp91
phox+/+
 on Normal Diet; # P<0.05 vs. 
gp91
phox+/+
 on FF Diet. 
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3.2.6 In vivo inhibition of NADPH oxidase prevented hHcys-induced glomerular 
inflammation and injury 
As shown in Figures 11A and 11C, immunohistochemical analysis demonstrated that 
Hcys stimulation induced macrophage (F4/80+) and T-cell (CD43+) infiltration in the glomeruli 
of hHcys gp91
phox+/+
 mice. However, the glomeruli of gp91
phox−/−
 and gp91ds-tat-treated mice 
had significantly less macrophage and T-cell recruitment when compared to gp91
phox+/+
 mice on 
the FF diet. The summarized data were shown in Figures 11B and 11D. These results suggest 
that normal NADPH oxidase gene expression and activity are required for inflammasome 
activation and consequent inflammatory response, which includes macrophage and T-cell 
recruitment and aggregation in glomeruli of mice during hHcys.  
Next, we tested whether gp91
phox
 contributes to hHcys-induced glomerular injury. As 
shown in Figure 12, hHcys significantly increased the urinary protein and albumin in gp91
phox+/+
 
mice compared to normal diet-fed mice.  Mice treated with gp91ds-tat and gp91
phox−/−
 mice had 
significantly attenuated hHcys-enhanced urinary protein and albumin excretion in FF diet-fed 
mice, but had no effect in normal diet-fed mice (Figures 12A and 12B). Morphological 
examinations revealed a typical pathological change in glomerular sclerotic damage indicated by 
capillary collapse, fibrosis, cellular proliferation and mesangial cell expansion in glomeruli of 
hHcys gp91
phox+/+
 mice (Figure 12C). The average glomerular damage index was significantly 
higher in glomeruli of hHcys gp91
phox+/+ 
mice compared to normal diet-fed mice. However, in 
gp91
phox−/−
 or gp91ds-tat-treated mice, hHcys-induced glomerular injuries were significantly 
inhibited (Figure 12D). 
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Figure 11. Inhibition of NADPH oxidase expression and activity prevented hHcys-
induced infiltration of macrophages and T-cells into the glomeruli.  A. gp91ds-tat and 
gp91
phox−/−
 mice prevented the increased expression and staining of macrophage marker F4/80 
that is seen in gp91
phox+/+
 on FF Diet.  B. Summarized counts of F4/80 positive glomeruli 
(n=6).  C. gp91ds-tat and gp91
phox−/−
 mice prevented the increased expression and staining of 
T-cell marker CD43 that is seen in gp91
phox+/+
 on FF Diet.  D. Summarized counts of CD43 
positive glomeruli (n=6). * P<0.05 vs. gp91
phox+/+
 on Normal Diet; # P<0.05 vs. gp91
phox+/+
 on 
FF Diet. 
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Figure 12. Inhibition of NADPH oxidase expression and activity protected glomerular 
function from hHcys-induced injury.  A. Hyperhomocysteinemic gp91
phox+/+ 
mice produced 
proteinuria, which was alleviated in the gp91
phox−/− 
or in the gp91ds-tat-treated mice (n=6).  B. 
Hyperhomocysteinemic gp91
phox+/+ 
mice produced albuminuria, where blockade of NADPH 
oxidase in gp91
phox−/− 
mice or in gp91ds-tat-treated mice prevented this glomerular damage 
(n=6).  C. Glomerular morphological examination by PAS staining demonstrated that gp91ds-
tat administration or gp91
phox−/−
 mice prevented capillary collapse, fibrosis, cellular 
proliferation and expansion induced by hHcys (n=4-6).  D. Glomerular damage index (GDI) 
was assessed by a standard semiquantitative analysis to determine severity of glomerular 
sclerosis. * P<0.05 vs. gp91
phox+/+
 on Normal Diet; # P<0.05 vs. gp91
phox+/+
 on FF Diet. 
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3.3 Summary 
In summary, these studies demonstrated that at the very early stages of glomerular damage, 
Hcys in vitro or hHcys in vivo stimulated the formation and activation of the NLRP3 
inflammasome, which initiated early injurious events in podocytes and glomeruli, leading to 
more serious glomerular injury and ultimate sclerosis. This NLRP3 inflammasome activation, 
podocyte injury, and the glomerular pathology induced by hHcys could be substantially 
suppressed by inhibition of NADPH oxidase. These results may establish a new concept that 
NADPH oxidase-derived ROS upon Hcys stimulation trigger the formation and activation of 
NLRP3 inflammasomes and thereby produce IL-1β and other factors, leading to podocyte and 
glomerular injury, potentially progressing into glomerular sclerosis. 
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CHAPTER FOUR 
Contribution of endogenously produced reactive oxygen species to the activation of 
podocyte NLRP3 inflammasomes in hyperhomocysteinemia 
 
4.1 Rationale and Hypothesis 
Much evidence demonstrates that many inflammasome stimulators are also known to 
produce ROS, and the ROS model of inflammasome activation proposes NLRP3 to be a general 
sensor for changes in local and intracellular oxidative stress, allowing it to become activated in 
response to a diverse range of stimuli [126, 149, 181-182]. Although homocysteine (Hcys)-
induced ROS production in podocytes has been documented, it remains unknown how this Hcys-
induced ROS production is involved in the activation of NLRP3 inflammasomes in podocytes 
and ultimate glomerular injury. We have previously reported, and also shown above in Chapter 
3, that inhibition of NADPH oxidase prevented Hcys-induced podocyte dysfunction, and more 
recently confirmed that inhibition of NADPH oxidase and the downstream production of O2
•−
 
abrogates NLRP3 inflammasome formation and activation [48, 169]. However, it is still poorly 
understood which species of ROS is responsible for NLRP3 inflammasome activation and how 
ROS lead to the formation or activation of this inflammasome. In this regard, recent studies have 
indicated that ROS may serve as important signaling messengers and that O2
•−
 and hydrogen 
peroxide (H2O2) are common ROS that may act as second messengers to activate 
inflammasomes within podocytes. Hence, the present study, as depicted in Figure 13, sought to 
dissect the potential role of these endogenously produced ROS in Hcys-induced NLRP3 
inflammasome activation and to determine which ROS are required for glomerular injury 
associated with such activation of NLRP3 inflammasomes. 
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4.2 Results 
4.2.1 Reduction of intracellular O2
•− 
and H2O2 levels prevented Hcys-induced NLRP3 
inflammasome formation in podocytes 
Using the O2
•−
 dismutase mimetic TEMPOL, the H2O2 destroying enzyme catalase, or the 
•
OH scavenger TMTU, we tested whether Hcys-induced inflammasome formation and activation 
can be altered. By confocal microscopy analysis, we demonstrated that Hcys induced 
colocalization (yellow spots) of inflammasome molecules (NLRP3 (green) vs. ASC or caspase-1 
(red)) in podocytes compared to control cells, suggesting increased formation of NLRP3 
 
 
Figure 13. Representative schematic for ROS dissection in Aim 1. Deeper investigation in 
Aim 1 sought to understand which specific ROS are responsible for hHcys-induced NLRP3 
inflammasomes activation. 
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inflammasomes (Figure 14A). However, prior treatment of podocytes with TEMPOL or catalase 
blocked Hcys-induced colocalization of NLRP3 with ASC or caspase-1. In contrast, TMTU did 
not block Hcys-induced inflammasome formation, suggesting that O2
•−
 and H2O2, but not 
•
OH, is 
involved in Hcys-induced inflammasome formation in podocytes. The colocalization coefficient 
analyses were summarized and shown in Figure 14B. These effects are thought to originate from 
ROS derived by specific Nox2, and not Nox1 or Nox4, activation (Figure 15). Furthermore, this 
Hcys-induced Nox2 mRNA upregulation was unaffected by O2
•−
 scavenging, suggesting that the 
subsequent effects of scavenging these ROS are due to events occurring downstream of NADPH 
oxidase activation (Figure 15). 
To further confirm inflammasome formation in response to elevated Hcys, size exclusion 
chromatography was employed and further provided evidence that TEMPOL or catalase 
treatment prevented Hcys-induced inflammasome formation, as shown by the inhibited shift of 
ASC proteins into higher-molecular weight fractions (Figure 16B). These fractions are 
compared to a standard protein size marker in Figure 16A, a representative chromatogram where 
proteins that are part of the inflammasome complex elute within fractions 3-7 and are analyzed 
by SDS-PAGE. The intensity of bands were quantified and summarized in Figure 16C, showing 
that scavenging of O2
•−
 and H2O2, but not 
•
OH, was able to inhibit inflammasome formation in 
podocytes treated with Hcys. 
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Figure 14.  TEMPOL and catalase attenuated Hcys-induced inflammasome formation in 
podocytes.  A.  Confocal images representing the colocalization of NLRP3 (green) with ASC 
or caspase-1 (red) in cultured podocytes.  B.  Summarized data showing the fold change of 
PCC for the colocalization of NLRP3 with ASC and NLRP3 with caspase-1 (n=4). Ctrl: 
Control; Vehl: Vehicle; TMTU: tetramethylthiourea, PCC: Pearson coefficient correlation.  * 
P<0.05 vs. Control; # P<0.05 vs. Hcys. 
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Figure 15. Hcys specifically induced Nox2 mRNA expression.  A. As detected by real-time 
RT-PCR, 24 hr treatment of podocytes with 40 µM Hcys caused significant upregulation of 
Nox2, but not Nox1 or Nox4 (n=3). B. Scavenging of O2
•−
 by TEMPOL and PEG-SOD had 
no effect on Hcys-induced Nox2 mRNA upregulation (n=3). * P<0.05 vs. Ctrl. 
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Figure 16.  Size-exclusion chromatography demonstrated inhibition of Hcys-induced 
ASC protein redistribution after O2
•−
 and H2O2 scavenging.  A.  Representative 
chromatogram illustrating the elution profile of proteins from both a standard and podocyte 
sample taken from an absorbance of 280 nm.  Elution of a gel filtration standard allowed for 
the determination of the molecular mass of the samples.  B.  Western blot was performed on 
selected FPLC protein fractions and probed with an anti-ASC antibody. C.  Summarized data 
determined from the ASC band intensities of the inflammasome complex fractions (3-7) (n=4-
6). Ctrl: Control; Vehl: Vehicle; TMTU: tetramethylthiourea.  * P<0.05 vs. Control; # P<0.05 
vs. Hcys. 
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4.2.2 TEMPOL and catalase, but not TMTU or ebselen, blocked activation of NLRP3 
inflammasomes in podocytes 
Aside from measures of NLRP3 inflammasome formation, previous studies have indicated 
that caspase-1 activation and IL-1β production reflect the activation of NLRP3 inflammasomes 
[169, 183]. In the present study, we tested whether TEMPOL and catalase abolish Hcys-induced 
NLRP3 inflammasome activation. As shown in Figures 17A and 17B, Hcys treatment 
significantly increased caspase-1 activity and IL-1β production compared to control cells. 
However, pretreatment of podocytes with either TEMPOL or catalase significantly attenuated 
Hcys-induced increases in caspase-1 activity and IL-1β secretion, indicating that O2
•−
 and H2O2 
are necessary for the functionality of inflammasomes in response to Hcys. In addition, we also 
tested the role of another SOD mimetic MnTMPyP as well as cell permeable PEG-SOD in 
podocytes with or without Hcys stimulation. We found that pretreatment with either MnTMPyP 
or PEG-SOD significantly attenuated the Hcys-induced caspase-1 activity and IL-1β production 
(Figures 17C and 17D). We demonstrated that scavenging of 
•
OH
 
by TMTU or ONOO
−
 by 
ebselen did not have effects on Hcys-induced NLRP3 inflammasome formation and activation in 
podocytes. In the following in vivo studies, therefore, six groups of experiments are presented 
that include mice on the normal or FF diet with or without TEMPOL and catalase. 
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Figure 17.  Effects of ROS scavenging on caspase-1 activity and IL-1β secretion in the 
presence of Hcys.  A.  Caspase-1 activity, shown as folds versus Ctrl, measured in podocytes 
treated with Hcys in the presence of various ROS scavengers (n=6-8).  B.  IL-1β production 
measured in the supernatant of podocytes treated with Hcys in the presence of various ROS 
scavengers (n=6-8). C. Inhibition of O2
•−
 by MnTMPyP and PEG-SOD significantly inhibited 
Hcys-induced caspase-1 activation (n=3-4). D. Treatment of podocytes with either MnTMPyP 
or PEG-SOD prevented Hcys-induced maturation of IL-1β (n=4-5).Ctrl: Control; Vehl: 
Vehicle; TMTU: tetramethylthiourea.  * P<0.05 vs. Control; # P<0.05 vs. Hcys.  
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4.2.3 Inhibition of NLRP3 inflammasome formation and activation in the glomeruli of 
hyperhomocysteinemic mice by TEMPOL and catalase 
To further determine whether O2
•−
 and H2O2 are implicated in inflammasome formation 
and activation in vivo, C57BL/6J wild type mice were treated with TEMPOL or catalase and fed 
a normal diet (ND) or FF diet for 4 weeks. HPLC analysis revealed that folate free (FF) diet 
treatment significantly increased the plasma total Hcys levels in uninephrectomized C57BL/6J 
mice compared with ND fed mice. Neither uninephrectomy nor the treatment of TEMPOL or 
catalase altered the Hcys levels on either diet, indicating that any observed effects were not due 
to a reduction in plasma Hcys (Figure 18). As shown in Figure 19, the glomeruli of mice 
maintained on the FF diet had increased colocalization of NLRP3 with ASC or NLRP3 with 
caspase-1 compared to ND fed mice, suggesting the enhanced formation of NLRP3 
inflammasomes in glomeruli of hHcys mice. hHcys, known to cause podocyte injury, 
significantly decreased the amount of podocin staining in the glomeruli, thus resulting in 
minimal colocalization with inflammasome protein NLRP3 (Figure 20). However, the formation 
of hHcys-induced NLRP3 inflammasomes mainly occurred in podocytes within glomeruli, 
evidenced by the increased colocalization of NLRP3 with podocyte damage marker desmin 
(Figure 20). This colocalization of NLRP3 was not evident with either VE-cadherin or α-SMA, 
respective markers of glomerular endothelial and mesangial cells (data not shown). hHcys also 
resulted in podocyte injury, demonstrated by the increase in protein expression of podocyte 
damage marker desmin. Correspondingly, caspase-1 activity and IL-1β production were 
significantly enhanced in hHcys mice compared to normal diet fed mice, further confirming 
NLRP3 inflammasome activation (Figures 21A and 21B). Concurrent with this inflammasome 
activation, SOD-sensitive O2
•−
 production was 2.1 fold greater in mice fed the FF diet than those 
 63 
on the ND (Figure 21C). All of these hHcys-induced effects on parameters of inflammasome 
formation and activation were abolished by administration of either SOD mimetic TEMPOL or 
H2O2 decomposer catalase. Taken together, these data suggest that both O2
•−
 and H2O2 play a 
pivotal role in hHcys-induced NLRP3 inflammasome formation and activation in glomeruli of 
hHcys mice. 
 
 
Figure 18. Effects of uninephrectomy or in vivo TEMPOL and catalase administration 
on FF diet-induced plasma Hcys levels. A. Measured by HPLC, uninephrectomy had no 
effect on plasma Hcys levels in mice receiving either ND or FF diet (n=4-6). B. Mice 
maintained on the FF diet for 4 weeks displayed significantly elevated plasma Hcys 
concentrations compared to those on the ND. TEMPOL and catalase did not alter these levels 
either in the normal or FF diet mice (n=4-6). * P<0.05 vs. ND. 
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Figure 19. In vivo effect of O2
•−
 and H2O2 inhibition on hHcys-induced inflammasome 
formation in glomeruli of hyperhomocysteinemic mice. A.  Colocalization of NLRP3 
(green) with ASC or caspase-1 (red) in the mouse glomeruli of vehicle, TEMPOL, or 
catalase-treated mice fed a normal or FF diet.  B-C. Summarized data showing the correlation 
coefficient between NLRP3 with ASC or caspase-1 (n=6). Casp1: caspase-1, Vehl: Vehicle, 
ND: Normal diet, FF: Folate-free diet. *P<0.05 vs. Vehl on ND; # P<0.05 vs. Vehl on FF 
Diet. 
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Figure 20. hHcys-induced inflammasome formation occurred primarily in podocytes of 
hyperhomocysteinemic mice. A.  Colocalization of NLRP3 (green) with podocyte markers 
podocin or desmin (red) in the mouse glomeruli of vehicle, TEMPOL, or catalase-treated 
mice fed a normal or FF diet.  B-C. Summarized data showing the correlation coefficient 
between NLRP3 with podocin or desmin (n=6). Podo: Podocin; Des: Desmin, Vehl: Vehicle, 
ND: Normal diet, FF: Folate-free diet. *P<0.05 vs. Vehl on ND; # P<0.05 vs. Vehl on FF 
Diet.  
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Figure 21. In vivo administration of TEMPOL and catalase prevented caspase-1 
activation, IL-1β production, and O2
•−
 production. A.  Caspase-1 activity in Vehl, 
TEMPOL, or catalase-treated mice with hHcys induced by the FF diet (n=7).  B. TEMPOL 
and catalase administration prevented hHcys-induced IL-1β production (n=6-7). C. O2
•−
 
production induced by hHcys was inhibited in mice treated with TEMPOL or catalase (n=6). 
Vehl: Vehicle, ND: Normal diet, FF: Folate-free diet. *P<0.05 vs. Vehl on ND; # P<0.05 vs. 
Vehl on FF Diet. 
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4.2.4 In vivo TEMPOL and catalase administration protected mouse glomeruli from 
hHcys-induced dysfunction and injury 
As shown in Figure 22, FF diet-induced hHcys resulted in significantly elevated urinary 
protein excretion as well as marked pathological changes in glomerular morphology, compared 
to mice on the ND. However, hHcys-induced proteinuria and glomerular injury were not evident 
in hyperhomocysteinemic mice treated with TEMPOL or catalase. Dismutation of O2
•−
 and 
decomposition of H2O2 was able to prevent hHcys-induced renal dysfunction and glomerular 
damage, signifying the importance of O2
•−
 and H2O2 in the mechanism of hHcys-induced injury. 
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Figure 22. Renal protective effects of O2
•−
 and H2O2 inhibition on hHcys-induced 
glomerular injury.  A. hHcys-induced proteinuria was attenuated in mice receiving 
TEMPOL or catalase treatment (n=6).  B. Microscopic observation of glomeruli in PAS 
stained kidney sections demonstrated TEMPOL and catalase prevented hHcys-induced 
changes in glomerular morphological structure by preventing capillary collapse, fibrosis, 
cellular proliferation and mesangial cell expansion (n=4-6). C. Extent of glomerular sclerosis 
was assessed semiquantitatively and expressed as the Glomerular damage index (GDI). Vehl: 
Vehicle, ND: Normal diet, FF: Folate-free diet.  *P<0.05 vs. Vehl on ND; # P<0.05 vs. Vehl 
on FF Diet. 
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4.3 Summary 
In summary, this series of studies demonstrated that reducing O2
•−
 and H2O2
 
inhibited 
NLRP3 inflammasome formation and consequent processing of IL-1β, suggesting that both 
species
 
are importantly implicated in the instigation of Hcys-induced NLRP3 inflammasome 
activation in cultured podocytes. Similar effects were seen in vivo in glomerular podocytes of 
hyperhomocysteinemic mice, where dismutation of O2
•−
 by TEMPOL and decomposition of 
H2O2 by catalase not only prevented glomerular NLRP3 inflammasome formation and activation, 
but also importantly protected against hHcys-induced glomerular injury and dysfunction. 
Together, these results indicate that O2
•−
 and H2O2 contribute to inflammasome triggering and 
consequent podocyte injury, ultimately leading to the potential progression toward glomerular 
sclerosis and ESRD during hHcys. 
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CHAPTER FIVE 
NLRP3 inflammasome activation and podocyte injury via thioredoxin-interacting protein 
during hyperhomocysteinemia 
 
5.1 Rationale and Hypothesis 
Thus far, this hHcys-induced NLRP3 inflammasome activating process was shown to 
depend on NADPH oxidase and the reactive oxygen species (ROS) derived from its activation, 
specifically O2
•−
 and H2O2, where inhibition of the gp91
phox
 subunit of NADPH oxidase or 
scavenging of O2
•−
 and H2O2 suppressed NLRP3 inflammasome activation and furthermore 
ameliorated subsequent glomerular dysfunction [169-170]. However, the exact mechanism of 
how the NADPH oxidase-derived ROS are sensed by podocytes to form and activate the NLRP3 
inflammasome and thereby lead to its activation in glomerular podocytes is still largely 
unknown. In this regard, the work done by Zhou et al provided strong evidence of thioredoxin-
interacting protein (TXNIP) as a binding partner to NLRP3, where association between these two 
proteins was necessary for downstream inflammasome activation [126]. TXNIP, the negative 
regulator of the antioxidant thioredoxin (TRX), may time-dependently dissociate from TRX to 
bind with NLRP3 leading to inflammasome formation and activation. In this series of studies, we 
attempted to investigate the role of TXNIP during hHcys and to explore its potential effects on 
NLRP3 inflammasome activation and consequent podocyte injury and glomerular sclerosis 
(Figure 23). We first characterized the feature of TXNIP binding to NLRP3 and its related role 
in the formation and activation of NLRP3 inflammasomes using cultured podocytes. Then, we 
determined the pathological role of TXNIP-mediated activation of NLRP3 inflammasomes in 
mice with hHcys. These studies together elucidate the key role of TXNIP in bridging redox 
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signals with activation of NLRP3 inflammasomes leading to podocyte injury and ultimate 
glomerular sclerosis. 
 
 
 
 
 
 
 
 
 
Figure 23. Diagram showing the potential TXNIP involvement in Aim 1. Further studies 
in Aim 1 will elucidate the potential role of TXNIP-NLRP3 binding in this mechanism of 
hHcys-induced NLRP3 inflammasome activation and subsequent glomerular injury. 
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5.2 Results 
5.2.1 TXNIP inhibition prevented TXNIP protein recruitment to NLRP3 inflammasome 
fractions 
In the chromatogram illustrating a typical standard and sample elution profile, the elution 
of inflammasome proteins in earlier fractions signifies the aggregation of inflammasome proteins 
to higher molecular weight complexes and the formation of inflammasomes (Figure 24A). 
Demonstrated by SEC in previous studies, Hcys stimulation of podocytes resulted in increased 
NLRP3 inflammasome formation [49, 169]. The present study further validated this concept as 
shown by the increased expression of NLRP3 protein in fractions 4-7, termed the inflammasome 
fractions in Hcys-treated podocytes (Figure 24B). In these podocytes stimulated by Hcys, we 
observed increased expression of TXNIP as well as the recruitment of TXNIP to the 
inflammasome fractions, suggesting TXNIP aggregation to the NLRP3 inflammasome complex. 
To further elucidate the role of TXNIP, we pretreated Hcys-stimulated podocytes with siRNA or 
verapamil to inhibit its expression and found that inhibition of TXNIP not only prevented its own 
shift to the inflammasome fractions, but also blocked the formation of NLRP3 complex in 
podocytes in response to Hcys stimulations. The relative band intensities at fractions 4-7 were 
quantified and summarized in Figure 24C. These SEC results provided strong evidence for a 
possible role of TXNIP and its aggregation with the inflammasome complex in Hcys-induced 
NLRP3 inflammasome formation. 
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Figure 24. TXNIP and NLRP3 recruitment to the high molecular weight inflammasome 
fractions upon stimulation with Hcys. A. SEC chromatogram illustrating the elution curves 
of a typical standard and podocyte protein sample. B. Representative Western blot gel 
documents depicting the shift of NLRP3 and TXNIP protein during Hcys treatment, which 
was prevented during TXNIP inhibition. C. Summarized quantification of either NLRP3 or 
TXNIP protein residing in the inflammasome fractions (n=4). Ctrl: Control, Vehl: Vehicle, 
TXNIPsi: TXNIP siRNA. * P<0.05 vs. Ctrl, # P<0.05 vs. Hcys. 
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5.2.2 Inhibition of Hcys-induced TXNIP-NLRP3 binding and NLRP3 inflammasome 
formation upon TXNIP blockade 
As an additional method for detection of NLRP3 inflammasome formation, confocal 
microscopy was used to observe the colocalization of inflammasome proteins in podocytes. 
Shown in Figure 25A, Hcys increased the colocalization of NLRP3 (green) and ASC (red) 
compared to control cells, suggesting the formation of NLRP3 inflammasomes in podocytes. 
Furthermore, Hcys stimulation also increased the colocalization of NLRP3 (green) with TXNIP 
(red), suggesting that Hcys induces the aggregation of TXNIP together with NLRP3. However, 
prior treatment with TXNIP siRNA or verapamil significantly attenuated the colocalization of 
NLRP3 with either ASC or TXNIP. This reveals that TXNIP expression and its binding to 
NLRP3 are necessary for NLRP3 inflammasome formation in Hcys-treated podocytes. The 
colocalization of NLRP3 with ASC and NLRP3 with TXNIP was quantified and summarized in 
Figures 25B and 25C. 
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Figure 25. TXNIP inhibition prevented Hcys-induced NLRP3 inflammasome formation. 
A. Confocal microscopic detection of NLRP3 (green) with ASC (red) and NLRP3 (green) 
with TXNIP (red) and their colocalization together (yellow), indicative of the inflammasome 
formation. B-C. Summarized data showing the quantification of the extent of colocalization 
between NLRP3 with ASC and NLRP3 with TXNIP (n=4-6). Ctrl: Control, Vehl: Vehicle, 
TXNIPsi: TXNIP siRNA. * P<0.05 vs. Vehl-Ctrl, # P<0.05 vs. Vehl-Hcys. 
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5.2.3 Blocking TXNIP abrogated Hcys-induced increases in caspase-1 activity and IL-1β 
secretion 
It is known that the formation of NLRP3 inflammasomes results in downstream caspase-1 
activation and subsequent IL-1β maturation. These effects reflect the functionality of the formed 
inflammasomes and thus were used to determine the effect of TXNIP inhibition on Hcys-induced 
inflammasome activation in the current study. Hcys treatment significantly increased caspase-1 
activity and IL-1β production in podocytes compared to control cells, suggesting activation of 
NLRP3 inflammasomes (Figures 26A and 26B). Both TXNIP siRNA transfection and 
pretreatment with verapamil significantly attenuated Hcys-induced caspase-1 activity and IL-1B 
production. 
 
 
Figure 26. Attenuation of Hcys-induced NLRP3 inflammasome activation by TXNIP 
blockade. A. Effect of TXNIPsi and verapamil on Hcys-induced NLRP3 inflammasome 
activation, shown as the fold change of caspase-1 activation versus Vehl-Ctrl (n=7-8). B. 
Measured in the supernatant of cultured podocytes, TXNIP inhibition suppressed Hcys-
induced IL-1β production (n=8). Ctrl: Control, Vehl: Vehicle, TXNIPsi: TXNIP siRNA. * 
P<0.05 vs. Vehl-Ctrl, # P<0.05 vs. Vehl-Hcys. 
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5.2.4 Protection from Hcys-induced podocyte damage by TXNIP inhibition 
To assess the extent of podocyte damage, the protein expression of slit diaphragm 
molecules like podocin and desmin was monitored. Podocin, a podocyte-specific marker, 
decreases in expression during injury, while podocyte damage marker desmin increases during 
injury [184-185]. Immunofluorescence analysis demonstrated that Hcys-treated podocytes 
displayed a dramatic decrease in podocin staining and increase in desmin staining, signifying 
podocyte damage (Figure 27A). However, TXNIP inhibition resulted in the reversal of these 
podocyte damages as shown by restoration of podocin and desmin protein expression to control 
levels. Quantification of fluorescence was summarized in Figure 27B. Moreover, the ability of 
podocytes to secrete VEGF is considered to be an additional measure of podocyte functionality 
[186]. Hcys-injured podocytes displayed impaired secretion of VEGF, which was precluded in 
TXNIP siRNA or verapamil treated cells (Figure 27C). Together, these data suggest that TXNIP 
mediates Hcys-induced podocyte dysfunction and that inhibition of TXNIP ameliorates the 
deleterious effects of Hcys or inflammation activation on podocytes. 
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Figure 27. Inhibition of TXNIP preserved podocyte integrity. A. Immunofluorescence 
staining of podocyte-specific marker podocin and podocyte injury marker desmin, where 
Hcys-induced decrease in podocin and increase in desmin expression were attenuated by 
TXNIPsi and verapamil. B. Summarized data showing the relative intensity of podocin and 
desmin staining (n=6). C. VEGF was measured in the supernatant of podocytes and used as an 
indicator of podocyte functionality, where Hcys-damaged podocytes suppressed VEGF 
secretion, which was restored upon TXNIP inhibition (n=6). Ctrl: Control, Vehl: Vehicle, 
TXNIPsi: TXNIP siRNA. * P<0.05 vs. Vehl-Ctrl, # P<0.05 vs. Vehl-Hcys. 
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5.2.5 Local in vivo TXNIP shRNA transfection inhibited TXNIP mRNA and protein 
expression in mouse kidneys 
To further determine the role of TXNIP in NLRP3 inflammasome activation and 
glomerular injury in mice, we transfected TXNIP shRNA into the kidney via the renal artery to 
locally silence the TXNIP gene. Our previous reports have demonstrated that introduction of 
plasmids locally into mouse kidneys by the ultrasound-microbubble technique displayed stable 
expression of transfected gene for at least 4 weeks [187]. In order to monitor plasmid 
transfection efficiency, a plasmid with a luciferase expression vector was cotransfected together 
with the targeting TXNIP shRNA plasmid to act as a reporter. Figure 28A represents in vivo 
imaging of gene expression in mouse kidneys monitored 3, 7, and 14 days post-transfection by 
an IVIS rodent animal imaging system. In a semidissected kidney 4 days after transfection, a 
strong luciferase signal was detected in the renal cortex, where the observed signal represents 
efficient transfection and gene expression (Figure 28B). It was demonstrated that efficient 
transfection of plasmids and gene expression were maintained throughout experiments and such 
in vivo imaging of gene expression was used to determine whether mice can continue for further 
functional studies. After transfected mice were maintained on either a normal or FF diet for 4 
weeks, the TXNIP mRNA levels in the kidney were assessed by real time RT-PCR to validate 
the efficiency of plasmid transfection and gene expression. As shown in Figure 28C, TXNIP 
shRNA transfection significantly decreased TXNIP mRNA expression in mice on the ND when 
compared to those transfected only with luciferase plasmids. Although TXNIP mRNA 
expression increased in luciferase-transfected mice maintained on the FF diet, TXNIP shRNA-
transfected mice exhibited substantially reduced TXNIP mRNA expression. These findings were 
translated to the protein level, demonstrated by immunofluorescent staining of TXNIP in the 
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glomeruli of transfected mice (Figure 28D). Together, we concluded that TXNIP shRNA is 
efficiently delivered locally to the mouse kidney and successfully being expressed, as evidenced 
by the markedly reduced TXNIP expression in glomeruli of mice. 
 
 
Figure 28. Efficiency of local in vivo transfection of TXNIP shRNA into the renal cortex 
by the ultrasound-microbubble technique. A. Images taken 3, 7, and 14 days post-
transfection by an in vivo imaging system daily confirmed transfection efficiency. B. Ex vivo 
image 4 days after transfection of semidissected kidney demonstrated successful localized 
gene expression. C. Real time RT-PCR data quantifying mRNA silencing efficiency of the 
plasmid after 4 weeks of maintenance on either a ND or FF diet (n=6). D. Immunofluorescent 
staining of TXNIP in the glomeruli of transfected mice. ND: Normal diet, FF: Folate-free diet, 
Luci: Luciferase, TXNIPsh: TXNIP shRNA. * P<0.05 vs. Luci-ND. 
 81 
5.2.6 Effect of in vivo TXNIP inhibition on hHcys-induced TXNIP-NLRP3 binding and 
NLRP3 inflammasome formation in glomeruli 
After 4 weeks of uninephrectomized mice receiving the FF diet regiment, mice developed 
hHcys which resulted in NLRP3 inflammasome formation in their glomeruli, mainly in 
podocytes as shown in our previous studies [49, 170]. Illustrated in Figure 29A, confocal 
microscopic analysis demonstrated that FF diet-fed mice increased colocalization of NLRP3 with 
ASC (increased yellow staining) in glomeruli of luciferase transfected mice compared to ND fed 
mice, suggesting glomerular NLRP3 inflammasome formation during hHcys. This was further 
accompanied with an increase in TXNIP expression, which colocalized significantly with 
NLRP3, and possible binding to the NLRP3-ASC-caspase-1 inflammasome complex. However, 
TXNIP inhibition (either by verapamil or TXNIP shRNA transfection) substantially suppressed 
colocalization of NLRP3 with either ASC or TXNIP (Figure 29A). This colocalization was 
quantified and summarized in Figure 29B and 29C. Further exemplified by co-
immunoprecipitation studies, hyperhomocysteinemic mice displayed robust amounts of TXNIP 
protein pulled down together with NLRP3 compared to ND fed mice, suggesting that NLRP3-
TXNIP binding was enhanced during hHcys (Figure 29D). However, this enhanced NLRP3-
TXNIP binding was not observed in glomeruli of TXNIP shRNA transfected or verapamil 
treated mice. 
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Figure 29. In vivo inhibition of TXNIP and its effect on NLRP3 inflammasome 
formation. A. Confocal microscopy demonstrated the colocalization between NLRP3 (green) 
with ASC (red) and NLRP3 (green) with TXNIP (red) in the glomeruli of Luci, TXNIPsh, and 
verapamil treated mice maintained on either a ND or FF diet. B-C. Summarized data showing 
the quantification of the extent of colocalization between NLRP3 with ASC and NLRP3 with 
TXNIP (n=6). D. Co-immunoprecipitation studies demonstrated robust in vivo TXNIP-
NLRP3 binding in mice with hHcys, which was not evident after TXNIP inhibition (n=5). 
ND: Normal diet, FF: Folate-free diet, Luci: Luciferase, TXNIPsh: TXNIP shRNA. * P<0.05 
vs. Luci-ND, # P<0.05 vs. Luci-FF. 
 83 
5.2.7 TXNIP inhibition diminished renal caspase-1 activation and IL-1β secretion 
induced by hHcys 
Caspase-1 activity and IL-1β production was measured to evaluate the effects of in vivo 
TXNIP inhibition on hHcys-induced NLRP3 inflammasome activation (Figure 30A and 30B). 
Mice with hHcys induced by the FF diet displayed increased caspase-1 activation and IL-1β 
production compared to those on the ND, suggesting increased NLRP3 inflammasome activity in 
the cortical tissue. This activation was not apparent in the mice where TXNIP was inhibited by 
either shRNA transfection or verapamil treatment. 
 
 
 
Figure 30. In vivo TXNIP shRNA transfection and verapamil treatment blocked 
caspase-1 activation and IL-1β production. A. Caspase-1 activity, shown as fold change 
versus Luci-ND, in Luci, TXNIPsh, and verapamil-treated mice with FF diet-induced hHcys 
(n=5-6). B. In vivo TXNIP inhibition prevented hHcys-induced IL-1β production (n=6). ND: 
Normal diet, FF: Folate-free diet, Luci: Luciferase, TXNIPsh: TXNIP shRNA. * P<0.05 vs. 
Luci-ND, # P<0.05 vs. Luci-FF. 
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5.2.8 Attenuation of hHcys-induced glomerular dysfunction by TXNIP inhibition 
As shown above and documented by many of our previous studies, the 
hyperhomocysteinemic mouse model successfully induced significant glomerular dysfunction 
and ultimate sclerosis [48, 169, 179]. Demonstrated in Figures 31A and 31B, luciferase 
transfected mice on the FF diet also exhibited severe urinary protein and albumin excretion 
compared to control mice on the ND, suggesting glomerular injury or dysfunction. Furthermore, 
mice with hHcys displayed aberrant glomerular morphology, characterized by a shrunken 
phenotype with extracellular matrix and collagen deposition, capillary collapse, and mesangial 
cell expansion (Figure 31C). Decreased expression of podocyte specific marker, podocin and 
increase in podocyte damage marker, desmin, both hallmarks of podocyte injury, were also 
observed in the glomeruli of mice on the FF diet (Figures 31E and 31F). In vivo TXNIP 
inhibition by shRNA transfection or verapamil treatment was able to prevent all of the 
aforementioned destructive changes induced by hHcys as shown by the reduction of proteinuria, 
albuminuria, glomerular pathological changes, and restored expression of podocin and desmin. It 
should be noted that all of these observed effects occurred independently of changes to blood 
pressure, as there was no measurable difference in mean arterial pressure between all groups of 
mice (data not shown). These data provided solid evidence that TXNIP plays a detrimental role 
in hHcys-induced podocyte and glomerular damage, which is due to its ability to mediate 
NLRP3 inflammasome activation. 
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Figure 31. Amelioration of hHcys-induced glomerular damage by in vivo TXNIP 
inhibition. A-B. hHcys-induced increases in proteinuria and albuminuria were diminished by 
TXNIPsh transfection and verapamil administration (n=6-8). C. Observation of glomerular 
morphology in PAS stained slides revealed severe pathological changes in the glomeruli of 
Luci-FF mice, which were prevented in TXNIP inhibited mice. D. Pathological changes in the 
glomeruli were semiquantitatively scored and summarized as the glomerular damage index 
(GDI) (n=5). E-F. In vivo immunofluorescent staining of podocin and desmin to assess 
glomerular podocyte condition (n=6). ND: Normal diet, FF: Folate-free diet, Luci: Luciferase, 
TXNIPsh: TXNIP shRNA. * P<0.05 vs. Luci-ND, # P<0.05 vs. Luci-FF. 
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5.3 Summary 
Taken together, we provided direct evidence that inhibition of TXNIP and diminished 
TXNIP-NLRP3 binding reduced NLRP3 inflammasome formation and activation, even in the 
continued presence of elevated Hcys or during hHcys in mice. This reduction in TXNIP–
mediated inflammasome activation protected podocytes from the early deleterious effects of 
Hcys that, if left unattended, may ultimately progress to glomerular sclerosis and potential 
ESRD. 
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CHAPTER SIX 
Contribution of guanine nucleotide exchange factor Vav2 to hyperhomocysteinemia-
induced NLRP3 inflammasome activation 
 
6.1 Rationale and Hypothesis 
Our evidence thus far demonstrated that NADPH oxidase-derived reactive oxygen species 
(ROS) mediate the activation of podocyte NLRP3 inflammasomes in response to elevated levels 
of Hcys or in vivo during hHcys. Our laboratory has also previously provided evidence that the 
guanine nucleotide exchange factor Vav2 exhibits high specificity to Rac1-mediated NADPH 
oxidase activation by elevated Hcys [44]. Vav2 overexpression alone and its subsequent NADPH 
oxidase activation were able to cause glomerular injury, even without the presence of hHcys. 
However, it remains unknown whether NADPH oxidase activator, Vav2, is involved in NLRP3 
inflammasome activation. Therefore, this last series of studies was designed to further validate 
the central role of NADPH oxidase by testing whether its molecular activator, Vav2 contributes 
to hHcys-induced NLRP3 inflammasome activation.  In order to test this hypothesis, which is 
schematically represented in Figure 32, podocytes were transfected with either a scramble, 
constitutively active form of Vav2 (oncoVav2) or Vav2 shRNA plasmid directly to the nucleus 
via nucleofection. Mice were also locally transfected with either the oncoVav2 or Vav2sh 
plasmid into the renal cortex, maintained on the normal or FF diet to induce hHcys, and then 
assessed for NLRP3 inflammasome formation and activation after 4 weeks of treatment. 
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6.2 Results 
6.2.1 OncoVav2 induced NLRP3 inflammasome activation and podocyte injury 
As demonstrated earlier, Hcys treatment of podocytes significantly increased NLRP3 
inflammasome activation measured through caspase-1 activation and IL-1β production (Figures 
33A and 33B). We now found that the inhibition of Vav2 attenuated both of these measures of 
inflammasome activation. Additionally, overexpression of Vav2 by nucleofection of the 
oncoVav2 plasmid resulted in increased caspase-1 activity and IL-1β secretion even in the 
absence of Hcys, importantly suggesting that NADPH oxidase activation alone is sufficient to 
stimulate NLRP3 inflammasome activation. Hcys treatment or oncoVav2 nucleofection also 
caused podocyte dysfunction, seen in the impaired ability of these podocytes to secrete VEGF 
 
Figure 32. Diagram showing the participation of Vav2 in NLRP3 inflammasome 
activation. Aim 3 tested whether enhanced NADPH oxidase activity via Vav2 
overexpression, both in vitro and in vivo, is sufficient to cause NLRP3 inflammasome 
activation. Additionally, Aim 3 further confirmed the central role of NADPH oxidase by 
looking at the effect of Vav2 inhibition. 
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(Figure 33C). Inhibition of Vav2, however, protected podocytes from this injury and restored 
VEGF secretion levels. Altogether, these in vitro results demonstrate an essential role for Vav2 
in Hcys-induced NLRP3 inflammasome activation and podocyte injury. 
 
Figure 33. Overexpression of Vav2 induced NLRP3 inflammasome activation and 
podocyte injury. A-B. Hcys treatment of podocytes, as well as oncoVav2 nucleofection 
alone, increased caspase-1 activation and IL-1β production, which was inhibited upon Vav2sh 
nucleofection. (n=4-5). C. Inhibition of Vav2 protected podocytes from Hcys-induced 
dysfunction, seen in restored levels of VEGF secretion (n=5). Ctrl: Control, Scram: Scramble, 
Vav2sh: Vav2 shRNA. * P<0.05 vs. Scram-Ctrl, # P<0.05 vs. Scram-Hcys. 
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6.2.2 In vivo inhibition of Vav2 prevented glomerular NLRP3 inflammasome formation 
and activation 
Through confocal microscopy observation, mice maintained on the FF diet exhibited 
glomerular NLRP3 inflammasome formation and increased colocalization between NLRP3 with 
ASC and NLRP3 with caspase-1 (Figure 34A). Mice locally transfected with oncoVav2 plasmid 
displayed a similar pattern of NLRP3 inflammasome formation despite not being 
hyperhomocysteinemic, suggesting that Vav2 overexpression-induced activation of NADPH 
oxidase is adequate to form NLRP3 inflammasomes regardless of elevated homocysteine. 
However, inhibition of Vav2 hindered hHcys-induced NLRP3 inflammasome formation, seen by 
reduced colocalization of NLRP3 with ASC or caspase-1, depicting an important role of Vav2 
and NADPH oxidase in the aggregation of inflammasome proteins in the glomeruli of 
hyperhomocysteinemic mice. This same pattern was observed for hHcys-induced NLRP3 
inflammasome activation and measurement of caspase-1 activation (Figure 34B). Finally, hHcys 
as well as oncoVav2 transfection induced glomerular dysfunction and albuminuria, which was 
diminished in Vav2sh-transfected mice (Figure 34C). Although our laboratory has already 
implicated an important role for Vav2 in hHcys-induced glomerular dysfunction [44], these data 
newly implicate a critical role for Vav2 in hHcys-induced glomerular NLRP3 inflammasome 
formation and activation. Additionally, in vivo NADPH oxidase activation via Vav2 
overexpression was sufficient to activate NLRP3 inflammasomes, signifying that these 
mechanisms can occur independently of elevated Hcys. 
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Figure 34. In vivo inhibition of Vav2 prevented glomerular NLRP3 inflammasome 
formation and activation. A-B. Mice with hHcys and those transfected with oncoVav2 
plasmid demonstrated increased NLRP3 inflammasome formation and activation, seen by 
increased colocalization (yellow staining) between inflammasome proteins NLRP3 with ASC 
and NLRP3 with caspase-1, as well as increased caspase-1 activation. These effects were 
inhibited upon Vav2sh transfection (n=4). C. hHcys-induced increases in albuminuria were 
diminished by Vav2sh transfection (n=4). ND: Normal diet, FF: Folate-free diet, Scram: 
Scramble, Vav2sh: Vav2 shRNA. 
 92 
6.3 Summary 
Together, these preliminary results indicate a necessary role for Vav2 in the activation of 
hHcys-induced NLRP3 inflammasomes via its activating action on NADPH oxidase, where 
inhibition of Vav2 can prevent its activation as well as the deleterious effects of Hcys on the 
glomeruli. These studies further validate the central role of NADPH oxidase activation in this 
mechanism of podocyte NLRP3 inflammasome activation. Importantly, experiments using 
oncoVav2 demonstrate that NADPH oxidase activation occurring independently of hHcys can 
also result in NLRP3 inflammasome formation and activation, suggesting that this redox 
activating mechanism of NLRP3 inflammasomes is not necessarily specific to Hcys alone, but 
perhaps to any activators of NADPH oxidase. 
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CHAPTER SEVEN 
DISCUSSION 
 
7.1 Role of NADPH oxidase in mediating NLRP3 inflammasome formation and 
activation in podocytes in response to elevated Hcys levels 
The primary goal of our first series of studies was to reveal whether NADPH oxidase-
mediated redox signaling contributes to Hcys-induced inflammasome formation or activation and 
consequent glomerular injury. In vitro studies using cultured podocytes and an in vivo animal 
model of hHcys demonstrated that NADPH oxidase is necessary for the formation and activation 
of NLRP3 inflammasomes in podocytes upon Hcys stimulation, thereby leading to podocyte 
dysfunction, glomerular immune cell recruitment, and ultimately glomerular injury and sclerosis.  
These results for the first time demonstrate Hcys-induced redox activation of podocyte NLRP3 
inflammasomes as an early mechanism switching on local inflammatory responses in glomeruli. 
  
hHcys has been known to directly cause deleterious effects in the kidney, promoting a 
vicious cycle responsible for chronic renal disease, where hHcys decreases renal function and 
leads to further increased plasma Hcys levels due to decreases in Hcys excretion in the kidney 
[18]. Our most recent work demonstrated through concentration and time dependent studies that 
in an in vitro setting, a 40 μM treatment for 24 hours in cultured podocytes is sufficient to 
activate an inflammasome-stimulating response, verifying the effect we have seen in vivo [49]. 
Indeed, the present study showed significant glomerular damage observed in gp91
phox+/+
 mice fed 
a FF diet for 4 weeks. Coinciding with this glomerular damage characterized by our laboratory 
and others to include mesangial cell expansion, overall cell proliferation, and capillary collapse 
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[48, 188], hHcys caused a significant increase in proteinuria and albuminuria, indicative of an 
impaired glomerular filtration membrane. In previous studies, these damaging effects of hHcys 
have been well correlated with its ability to stimulate the inflammatory response. 
Proinflammatory mediators, like MCP-1, NF-kB, interleukin-8, and adhesion molecules VCAM-
1 and E-selectin, have been demonstrated to be upregulated during hHcys [189-190]. 
Furthermore, it has been shown that hHcys results in the recruitment of lymphocytes [191].  
However, it remains unknown how hHcys or Hcys in vitro activates this response of the innate 
immune system in glomeruli. We have recently reported that Hcys can activate NLRP3 
inflammasomes in podocytes, an intracellular molecular switch of inflammation [49]. 
Inflammasome activation has also been implicated in a number of inflammatory and metabolic 
diseases, including obesity, gout, hypersensitivity, silicosis, and diabetes, where inhibition of the 
inflammasome proteins NLRP3, ASC, or caspase-1 significantly attenuates the downstream 
inflammatory reaction produced under these conditions [118, 120, 126-127].  Similarly, our 
report showed that inhibition of either ASC or caspase-1 could prevent podocyte and glomerular 
damage induced by hHcys, improving renal structural and functional integrity [49], suggesting 
an important role for inflammasome activation in mediating the deleterious effects of hHcys. 
 
We further explored the mechanism by which NLRP3 inflammasomes are activated in 
podocytes in vitro by Hcys and in vivo by experimental hHcys. It has been reported that many 
endogenous and exogenous danger signals activate the inflammasome, and it has been of great 
interest as to how all of these very diverse signals can activate the same molecular machinery to 
turn on inflammation. Of the proposed models of inflammasome activation, the ROS model 
provides a unifying link, utilizing the common aspect that all these danger signals produce 
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changes in oxidative stress, making NLRP3 a more general sensor detecting these changes in 
oxidative stress [149]. Interestingly, our laboratory and others have found the damaging effects 
of hHcys to be strongly associated with increased local oxidative stress, chiefly through NADPH 
oxidase [47, 64-65]. With reports of gp91
phox
/Nox2 being the predominant isoform found in 
podocytes, our laboratory has also demonstrated that this NADPH oxidase isoform and its 
activity are essential for hHcys to induce glomerular injury, since knockout of the gp91
phox
 gene 
in mice protected podocytes and glomeruli from hHcys-induced glomerular sclerosis [48]. 
Therefore, we hypothesized that redox signaling associated with NADPH oxidase in podocytes 
may be critical in triggering NLRP3 inflammasome formation and activation upon Hcys 
stimulation.  Although there are reports that NLRP3 inflammasomes can be activated by ROS in 
different cells or tissues [126, 149, 181], to our knowledge, our results for the first time link 
NADPH oxidase to the formation and activation of these inflammasomes in podocytes, where 
Hcys-induced NADPH oxidase activation produces O2
•−
 to conduct redox signaling that triggers 
the formation of NLRP3 inflammasomes and production of inflammatory cytokines like IL-1. 
 
Next, we tested the in vivo triggering action of NADPH oxidase activation in the formation 
of NLRP3 inflammasomes using mice lacking the gp91
phox 
gene and in mice treated with 
NADPH oxidase inhibitory peptide, gp91ds-tat. Although the strategies used to genetically and 
pharmacologically inhibit NADPH oxidase in mice were not podocyte-specific, confocal results 
demonstrated that this inhibition prevented hHcys-induced NLRP3 inflammasome formation as 
shown by less colocalization of NLRP3 with ASC and NLRP3 with caspase-1, which mainly 
occurred in podocytes given the increased colocalization of NLRP3 molecules with podocin and 
desmin within glomeruli. Correspondingly, both interventions also inhibited hHcys-induced 
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activation of NLRP3 inflammasomes, confirmed by decreased caspase-1 activity and IL-1β 
production. The inflammatory response in glomeruli during hHcys, indicated by recruitment of 
macrophages and T-cells, was also significantly suppressed by both RNA interference and 
pharmacological inhibition of NADPH oxidase. These results from in vivo animal experiments 
further support the view that NADPH oxidase-mediated redox signaling promotes the formation 
and activation of NLRP3 inflammasomes in podocytes during hHcys. Again, to our knowledge, 
these findings represent the first in vivo experimental evidence that triggering of NLRP3 
inflammasomes is attributed to NADPH oxidase-mediated redox signaling, which results in local 
inflammation in glomeruli during hHcys.  
 
We also performed in vitro and in vivo experiments to address the functional relevance of 
NADPH oxidase-mediated triggering of NLRP3 inflammasomes on Hcys-stimulated podocyte 
and glomerular injury. Podocytes, the epithelial cells lining the outermost layer of the glomeruli, 
are essential for proper filtration, and the injury to podocytes is indicative of impaired glomerular 
filtration and proteinuria, ultimately leading to glomerular sclerosis [192-193]. Foot process 
effacement, considered as the hallmark sign of podocyte injury, is usually accompanied by the 
destruction of the actin cytoskeleton, increased expression of slit diaphragm molecule and 
podocyte injury factor desmin, and reduction of the slit diaphragm molecule podocin, an 
important marker for cell polarity and survival. Although such protection of podocytes observed 
in in vivo experiments may be due to a suppressed inflammatory response, it is interesting to note 
that in in vitro experiments the direct effects of suppressed inflammasome or NADPH oxidase 
also protect the functional and structural integrity of podocytes, even before a typical 
inflammatory response is instigated. This non-inflammatory effect or direct action on podocytes 
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has been reported to be associated with IL-1β-induced podocyte dysfunction, which is beyond 
inflammation [194]. In addition to the detrimental actions of hHcys-induced inflammatory 
response, the early effect of activated inflammasome products, like IL-1β, directly on podocytes 
may also importantly contribute to podocyte injury. If triggering of such inflammasomes by 
NADPH oxidase-derived ROS is blocked, both direct and indirect effects of inflammasome 
activation in the induction of podocytes injury may be blocked, as shown in our results.  
 
Corresponding to protection of podocytes from Hcys-induced injury, inhibition of 
inflammasome activation by deletion of gp91
phox
 gene or inhibition of NADPH oxidase activity 
significantly ameliorated hHcys-induced glomerular injury in mice, which may be due to 
decreased podocyte injury as well as suppressed local glomerular inflammatory response. 
Together, this NADPH oxidase-derived ROS may act as redox signaling messengers to activate 
the NLRP3 inflammasome, which serves as the bridging and amplifying mechanism leading to 
an eventual robust inflammatory response which promotes the progression to glomerular 
sclerosis.  
 
7.2 Redox activation of NLRP3 inflammasomes in response to elevated Hcys or during 
hHcys depends on both O2
•−
 and H2O2  
The goal for this portion of the study was to dissect which endogenously produced ROS in 
response to increased Hcys in podocytes in vitro and in vivo contributes to hHcys-induced 
NLRP3 inflammasome formation and activation. Studies using cultured podocytes revealed that 
reduction of intracellular O2
•−
 and H2O2 levels attenuated Hcys-induced NLRP3 inflammasome 
formation and suppressed downstream caspase-1 activation and IL-1β production. In vivo, 
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dismutation of O2
•−
 and decomposition of H2O2 in hyperhomocysteinemic mice not only 
prevented NLRP3 inflammasome formation in glomeruli, but also protected mice with hHcys 
from renal dysfunction and glomerular sclerosis. To our knowledge, this study is the first effort 
to dissect endogenously produced ROS in NLRP3 inflammasome activation in podocytes and 
glomeruli during exposure to high Hcys levels or hHcys. 
 
Many studies provided increasing evidence for the central role of ROS in NLRP3 
inflammasome activation [126, 195-196]. Additional studies have demonstrated that IL-1β 
production in response to even more diverse stimuli could be prevented through the use of either 
NADPH oxidase inhibitors or general ROS scavengers such as diphenylene iodonium (DPI) and 
N-acetyl-cysteine (NAC) [151, 197-199]. However, by using these general ROS scavengers, it 
remains largely unexplored as to exactly which species of ROS is being sensed and is indeed 
contributing to NLRP3 inflammasome activation. Aside from O2
•−
, other species derived from 
NADPH oxidase include H2O2, peroxynitrite (ONOO
-
), and 
•
OH [200]. A small subset of reports 
has attempted the use of ROS scavengers, but to our knowledge, the present study is the first to 
dissect the action of these common endogenously produced ROS to elucidate their role in hHcys-
induced NLRP3 inflammasome activation. 
 
TEMPOL, used for its antioxidant properties, has been widely demonstrated to have 
protective effects against many disease models including diabetes, cardiovascular complications, 
heart failure, angiogenesis, ischemia-reperfusion injury, cancer, and glomerular injury [201-203]. 
Catalase is responsible for the enzymatic decomposition of H2O2 down to H2O and O2 [204-205], 
and TMTU has been used as a specific 
•
OH
 
scavenger [203]. These pharmacologic tools enabled 
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the dissection of the ROS participating in Hcys-induced NLRP3 inflammasome formation and 
activation. However, the use of TEMPOL is fairly limited in that its selectivity for O2
•−
 is quite 
restricted due to a number of nonspecific targets, hence our use of PEG-SOD as well as an 
additional SOD mimetic, MnTMPyP, in in vitro experiments to further verify our results. But, 
similar to our findings in podocytes or glomeruli, a recent report provided evidence that 
scavenging of extracellular O2
•−
 by SOD mimetic Mn(III)tetrakis(N-ethylpyridinium-2-yl) 
porphyrin (MnTE-2-PyP) could prevent NLRP3 inflammasome activation in a model of 
hypoxia-induced pulmonary hypertension [183]. In addition, Zhou et al demonstrated the ability 
of exogenous H2O2 to directly activate NLRP3 inflammasomes to produce IL-1β [126]. Taken 
together, these data suggest the requirement of O2
•−
 dismutation to H2O2 in ROS-stimulated 
inflammasomes, which proposes an important role for H2O2 not only in Hcys-induced NLRP3 
inflammasome formation, but also in inflammasome formation in response to other stimuli that 
increase H2O2 production. 
 
The 
•
OH scavenger TMTU did not significantly inhibit any measure of Hcys-induced 
NLRP3 inflammasome formation or activation, suggesting that in comparison to O2
•−
 and H2O2, 
•
OH
 
does not play a crucial role to inflammasome stimulation. Although TMTU did not produce 
inhibitory effects that were of statistical significance, caspase-1 activity and IL-1β production 
appeared lower when TMTU was used. This effect may be due to some non-specific action of 
TMTU because thiourea compounds, although commonly used as potent scavengers of 
•
OH, are 
also able to scavenge O2
•−
 and H2O2 at higher doses [206-207].  
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An important role for ONOO
-
 in many disease processes is supported throughout the 
literature, including Hcys-induced cardiovascular and renal injury where ONOO
- 
participates in 
detrimental events such as endothelial dysfunction and renal ischemia-reperfusion injury [208-
209]. Therefore, we examined the role of ONOO
-
 scavenging on Hcys-induced NLRP3 
inflammasome formation and activation in podocytes. It was found that ebselen, a specific 
ONOO
-
 scavenger, failed to decrease the formation and activation of NLRP3 inflammasomes in 
podocytes treated with Hcys, suggesting that ONOO
-
 may not play a critical role in this 
particular pathological process in podocytes. 
 
With respect to the models of NLRP3 inflammasome activation, there is debate whether 
pro- or antioxidant events contribute to this phenomenon. Our study, along with many of the 
aforementioned studies, provided supportive evidence for a ROS-dependent mechanism that can 
be hindered when these species are scavenged. This concept, however, has been challenged with 
evidence demonstrating that ROS inhibition prevents the priming, but not activation of 
inflammasomes [156]. Furthermore, monocytes and macrophages isolated from patients with 
chronic granulomatous disease and NADPH oxidase-deficient mice exhibited typical IL-1β 
secretion [119, 157], which was different from our results in podocytes [169]. It is possible that 
different cell types may have altered sensitivity to redox regulation of NLRP3 inflammasomes or 
to different danger signals. Activation of NLRP3 or other inflammasomes in macrophages in 
vitro may require a priming process, a step that perhaps is not necessary in other cell types [49, 
210]. In addition, since NLRP3 inflammasome activation only requires a low level of 
intracellular O2
•−
 or H2O2 as a signaling mechanism rather than a injurious event, monocytes and 
macrophages isolated from patients with chronic granulomatous disease and NADPH oxidase-
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deficient mice may still potentially generate enough ROS to stimulate NLRP3 inflammasome 
activation and IL-1β production. Perhaps other ROS-producing pathways in these sick cells may 
also exert compensatory redox regulation to NLRP3 inflammasome activation. Additional 
studies are needed to further explore such potential for the redox regulation of NLRP3 
inflammasomes in different cell types.  
 
These findings importantly implicate a specific role for both O2
•−
 and H2O2
 
in the 
instigation of NLRP3 inflammasome activation in cultured podocytes and in glomeruli of mice 
with hHcys. O2
•−
 and H2O2
 
may be the redox signaling messengers linking NADPH oxidase 
activation to the stimulation of the innate immune system through NLRP3 inflammasome 
activation, where initiation of the inflammatory response may lead to more extensive oxidative 
stress that is responsible for hHcys-induced detrimental and pathological glomerular changes. 
 
7.3 TXNIP senses redox signals to activate NLRP3 inflammasomes in response to 
increased Hcys in vitro or during hHcys in vivo  
Additional experiments in this study were designed to address the role of TXNIP in hHcys-
induced NLRP3 inflammasome activation and associated podocyte injury and glomerular 
sclerosis. It was found that Hcys treatment of podocytes upregulated protein expression of 
TXNIP, which resulted in increased binding of TXNIP with inflammasome protein NLRP3. Both 
in vitro and in vivo inhibition of TXNIP by its inhibitor verapamil or RNA interference blocked 
TXNIP expression and prevented TXNIP-NLRP3 binding and subsequent NLRP3 
inflammasome activation in response to Hcys. These findings demonstrate the critical role of 
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TXNIP binding in the activation of NLRP3 inflammasomes and subsequent podocyte injury and 
glomerular dysfunction or sclerosis. 
Despite studies that have demonstrated an important role for ROS in inflammasome 
activation, it remains unclear how NLRP3 is able to sense redox changes in a variety of cells, in 
particular, in podocytes during hHcys. Through a yeast two hybrid screen, it has been shown that 
thioredoxin-interacting protein (TXNIP), a ROS sensor and an endogenous inhibitor of the 
antioxidant thioredoxin, is a binding partner of NLRP3. TXNIP, also known as vitamin D3 
upregulated protein 1 (VDUP-1) and thioredoxin-binding protein-2 (TBP-2), plays a critical role 
in growth suppression, making it particularly important in cancer progression by causing G1 cell 
cycle arrest. It is also a crucial regulator of lipid metabolism where overexpression of TXNIP 
during hyperglycemia causing β-cell death and impaired insulin secretion [211]. Zhou et al 
confirmed an important role for TXNIP in the pathogenesis of type 2 diabetes by showing that 
TXNIP binding to NLRP3 was essential for ROS-mediated inflammasome activation [126]. 
Additionally, in human and rat kidneys, TXNIP mRNA and protein is most abundantly 
expressed in the glomeruli [212], and although some studies have demonstrated its upregulation 
in response to high glucose [213-214], there have been no studies to date determining the effects 
of Hcys on TXNIP, in particular, in podocyte or glomerular injury, which was one of the goals in 
the current study. 
 
Using RNA interference and pharmacologic inhibitors of TXNIP, we found that TXNIP 
mRNA and protein expression was significantly reduced after transfection of siRNA into 
cultured mouse podocytes (data not shown) and local transfection of TXNIP shRNA in vivo into 
mouse kidneys. To complement this RNA manipulation, we used pharmacologic calcium 
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channel blocker verapamil to inhibit TXNIP expression both in vitro and in vivo. It has been 
demonstrated that verapamil, when administered to mice through the drinking water at an 
average dose of 100 mg/kg/day, decreased diabetes-induced cardiomyocyte apoptosis, an effect 
specifically due to its potent inhibition of TXNIP expression [168]. Additionally, verapamil 
enhanced β-cell survival and function through its reduction of β-cell TXNIP expression [215], 
and this may be due to verapamil-induced transcriptional repression of TXNIP [216]. It was 
found that verapamil, at a dose of 50 μM, strongly inhibited TXNIP expression (data not shown), 
blocked TXNIP binding to NLRP3, and prevented Hcys-induced NLRP3 inflammasome 
formation and activation in podocytes. In vivo experiments furthermore displayed TXNIP 
inhibition hindering caspase-1 activation and IL-1β maturation in hyperhomocysteinemic mice. 
To our knowledge, this provides the first evidence showing the critical role of TXNIP-NLRP3 
binding in mediating podocyte inflammasome activation in response to Hcys stimulation. 
 
It is well known that prolonged elevation of blood homocysteine level results in hallmarks 
typical of glomerular sclerosis, including glomerular hypercellularity, capillary collapse, and 
fibrous extracellular matrix deposition [217-219]. However, inhibition of TXNIP by either 
genetic manipulation or by verapamil treatment prevented the Hcys-induced detrimental effects 
on both podocytes in culture and glomerular structure and function. Verapamil has long been 
demonstrated to have glomerular protective effects [220-221]; however, our study is the first to 
demonstrate that, at least in hHcys-induced glomerular injury, this protective effect of verapamil 
is associated with its inhibitory action of TXNIP. 
 
 104 
In other studies, inhibition of TXNIP expression by verapamil has also been reported [222], 
but this effect has been extended to other calcium channel blockers and inhibitors such as 
diltiazem and NiCl2, as well as with calcium chelator EGTA. This suggests that this inhibition of 
TXNIP function is perhaps not a direct effect of verapamil itself, but more likely due to a 
reduction in intracellular calcium concentrations [215]. Additionally, calcium signaling is 
emerging as an important component of NLRP3 inflammasome activation. Brough et al first 
demonstrated such role of calcium signaling when they found suppressed IL-1β maturation 
following pretreatment of cells with calcium chelator, BAPTA-AM [223]. This process may 
involve endoplasmic reticulum (ER) stress, calcium release from ER, and TXNIP binding [223-
225]. Although these possible non-specific effects of calcium inhibition may not be excluded, 
our multifaceted approach of genetic and pharmacologic interventions give us confidence that 
the diminished NLRP3 inflammasome activation by verapamil is indeed due to the reduction in 
TXNIP expression and binding. It should be noted that the contribution of various calcium 
signaling pathways in the mediation or regulation of NLRP3 inflammasome activation in 
podocytes or other cells indeed warrants future exploration. 
 
TXNIP binding to NLRP3 appears to be an essential mechanism involved in the regulation 
of NLRP3 inflammasome activation in response to elevated Hcys. TXNIP may initiate the 
NLRP3 cascade by endogenously sensing the altered redox status of the cell, triggering the 
secretion of pro-inflammatory cytokines like IL-1β to potentiate the inflammatory response. 
Inhibition of TXNIP not only prevented NLRP3 inflammasome activation and Hcys-induced 
podocyte injury in cultured cells, but also importantly preserved glomerular function and 
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morphology in hyperhomocysteinemic mice, suggesting a critical in vivo role for TXNIP in this 
sclerotic mechanism.  
 
7.4 Activation of NADPH oxidase by Vav2 overexpression is sufficient to activate 
NLRP3 inflammasomes in podocytes, independent of hHcys 
The further mechanistic studies on NLRP3 inflammasome activation were proposed to 
address the effect of NADPH oxidase activation through the overexpression of Vav2, which 
attempted to test whether NADPH oxidase activation by other stimuli also lead to NLRP3 
inflammasome activity in podocytes. In cultured podocytes and mice, oncoVav2 transfection was 
found to result in NLRP3 inflammasome formation and activation as well as glomerular 
dysfunction, independent of elevated Hcys. However, inhibition of Vav2 by RNA interference 
prevented hHcys-induced caspase-1 activation and protected from albuminuria, indicating 
NADPH oxidase activation alone can activate NLRP3 inflammasomes and Vav2 can stimulate 
hHcys-induced detrimental effects. 
 
There exists considerable controversy regarding the role of NADPH oxidase in the 
activation of NLRP3 inflammasomes in response to a diverse range of stimuli. There is evidence 
to suggest that NADPH oxidase and its gp91
phox
 subunit are dispensable in terms of NLRP3 
inflammasome activation. Wu et al demonstrated that mechanical ventilation causes IL-1β 
release in the lung; however, there was no inhibitory effect on released IL-1β in cyclic-stretched 
mouse alveolar macrophages isolated from gp91
phox−/−
 mice [158]. Instead, it was concluded that 
ROS derived from mitochondria was necessary for NLRP3 inflammasome activation induced by 
cyclic stretch. Furthermore, some studies showed that peripheral blood mononuclear cells 
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isolated from chronic granulomatous disease (CGD) patients exhibit normal secretion of IL-1β 
and even exacerbated caspase-1 activation when compared to healthy controls [157, 226-227]. 
Interestingly, in human neutrophils isolated from CGD patients having mutations in the gp91
phox 
subunit of NADPH oxidase displayed impaired IL-1β release but displayed no difference in the 
ability to activate caspase-1 when compared to neutrophils from control patients [228]. This 
suggested that NADPH oxidase, specifically gp91
phox
, and the production of ROS are 
dispensable for NLRP3 inflammasome activation, but crucial for IL-1β secretion. This finding is 
altogether different from Bauernfield et al who found that ROS is necessary for the priming and 
regulation of NLRP3 inflammasome protein expression, but not needed for its activation [156]. 
On the other hand, NADPH oxidase and gp91
phox
 are required for ATP-induced NLRP3 
inflammasome activation in LPS-primed murine macrophages, where general NADPH oxidase 
inhibitors DPI and apocynin as well as specific gp91
phox
 siRNA inhibited caspase-1 activation 
and IL-1β secretion [195]. Similar results have been found in response to many NLRP3 
inflammasome stimulators like TNF-α and free fatty acids, where the effects of these stimulators 
can be blocked upon NADPH oxidase inhibition [153-154]. With all these contradicting findings, 
we sought to better understand the role of NADPH oxidase in Hcys-induced NLRP3 
inflammasome activation in podocytes. Upon Vav2 overexpression, we found that NADPH 
oxidase activation alone led to caspase-1 activation and IL-1β production in cultured podocytes, 
indicating that NLRP3 inflammasome activation may vary with different stimuli, but if NADPH 
oxidase is activated, NLRP3 inflammasomes can become activated in podocytes. 
 
Rac1, considered the major Rac GTPase isoform in nonphagocytic cells, mediates NADPH 
oxidase activity by switching between a GTP-bound “active” and a GDP-bound “inactive” 
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conformational state. In the presence of various stimuli, guanine nucleotide exchange factors 
(GEFs) like Vav and Tiam1 are responsible for this switching of Rac/Rho GTPases, leading to 
multiple downstream effects limited not only to NADPH oxidase activation, but also regulating 
cellular processes including proliferation, differentiation, and cytoskeletal arrangement [229]. 
The Vav family of GEFs, exhibiting high specificity to Rac-mediated NADPH oxidase 
activation, consists of three members – Vav1, Vav2, and Vav3, with reports of Vav2 being 
importantly expressed in podocytes [230]. It has been demonstrated by Inoue et al that Rac1 
inhibitor NSC23766 suppressed ATP-induced ROS production and IL-1β secretion in bone 
marrow macrophages [231]. Additionally, macrophages isolated from NLRP3
−/−
 and ASC
−/−
 
mice demonstrated no changes in Rac or Vav expression or ROS production, strongly suggesting 
these molecules to be upstream of the NLRP3 inflammasome. Our results coincide with these 
recent findings, supporting the manipulation of GEF Vav2 as an effective approach in 
modulating NADPH oxidase activity. Indeed, we found that inhibition of Vav2 reduced NADPH 
oxidase-derived O2
•−
, attenuated caspase-1 activation and IL-1β production, and protected 
podocytes and mouse glomeruli from hHcys-induced injury. 
 
Collectively, through specific activation of NADPH oxidase by overexpression of Vav2, 
our studies provided strong evidence for a central and crucial role for NADPH oxidase in hHcys-
induced NLRP3 inflammasome activation. This stimulation of NADPH oxidase, independent of 
Hcys, importantly demonstrated that regardless of upstream stimulation, the activation of 
NADPH oxidase and the production of ROS are sufficient to stimulate aggregation and 
activation of NLRP3 inflammasomes. Therefore, these mechanisms may not be limited to only 
elevated Hcys, but to any stimulator of NADPH oxidase. 
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7.5 Summary and conclusions 
The major findings of the present study are summarized below, and represented in Figure 35. 
 
1. As previously demonstrated, we showed that hHcys-induced glomerular injury occured in an 
NLRP3 inflammasome-dependent mechanism. However, blockade of NADPH oxidase 
through the inhibition of its gp91
phox
 subunit attenuated Hcys-induced NLRP3 inflammasome 
activation in cultured podocytes as well as preserved podocyte function and integrity. In 
hyperhomocysteinemic mice, gp91
phox−/−
 as well as mice receiving a gp91ds-tat peptide 
displayed diminished NADPH oxidase activation, as exhibited through reduced O2
•−
 levels, 
which contributed to the reduction in NLRP3 inflammasome formation and activation in 
vivo. Together, these results reveal an essential role for NADPH oxidase activation and the 
production of local oxidative stress in the triggering of NLRP3 inflammasomes in response 
to hHcys. 
 
2. Dismutation of O2
•−
 by TEMPOL and decomposition of H2O2 by catalase prevented the 
colocalization of NLRP3 inflammasome proteins, and reduced caspase-1 activity and IL-1β 
production both in cultured podocytes and in glomeruli of hyperhomocysteinemic mice. 
Specific ROS scavenging studies revealed that O2
•−
 and H2O2, but not 
•
OH or ONOO
-
, 
distinctly contribute to NLRP3 inflammasome formation and activation during elevated 
Hcys.  
 
3. Through size-exclusion chromatography experiments, Hcys-treated podocytes exhibited both 
increased expression and recruitment of TXNIP to high molecular weight fractions, 
 109 
indicative of TXNIP aggregation to the NLRP3 inflammasome. Confirmed by co-
immunoprecipitation studies, robust increases in TXNIP-NLRP3 binding were found in 
cultured podocytes with Hcys exposure and in renal cortical tissue from 
hyperhomocysteinemic mice. Inhibition of TXNIP either by shRNA transfection or by 
verapamil administration blocked TXNIP-NLRP3 binding and interfered with NLRP3 
inflammasome activation, demonstrating the crucial role of TXNIP in hHcys-induced 
NLRP3 inflammasome activation. 
 
4. TXNIP expression was upregulated in podocytes in response to elevated Hcys, and in vivo 
TXNIP inhibition significantly preserved glomerular morphology and function during hHcys. 
FF diet-maintained mice receiving either TXNIP shRNA transfection or verapamil exhibited 
drastically reduced proteinuria and albuminuria, as well as protection from hHcys-induced 
glomerular sclerotic changes. To our knowledge, this is the first study elucidating that 
TXNIP inhibition is glomerular protective against hHcys-induced insult. 
 
5. The inhibition of guanine nucleotide exchange factor Vav2 prevented hHcys-induced NLRP3 
inflammasome formation and activation in both cultured podocytes and 
hyperhomocysteinemic mice, further verifying the important role of functional NADPH 
oxidase in this mechanism. However, overexpression of Vav2 and consequent activation of 
NADPH oxidase, independent of elevated Hcys, were also able to produce these 
inflammasome-activating effects, suggesting that NADPH oxidase activation alone via Vav2 
is sufficient to initiate the cascade that leads to NLRP3 inflammasome activation and 
downstream glomerular injury. 
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In conclusion, evidenced by gp91
phox
 and Vav2 inhibition, NADPH oxidase is 
demonstrated to be critical in mediating NLRP3 inflammasome formation, with O2
•−
 and H2O2 
being important signaling messengers. TXNIP may be the unique key that is responsible for 
sensing these changes in these signaling ROS and initiating the cascade of NLRP3 
inflammasome activation, eventually progressing to the pathogenesis of glomerular sclerosis 
during hHcys. Activation of NADPH oxidase via overexpression of Vav2 was sufficient to 
stimulate aggregation and activation of NLRP3 inflammasomes, suggesting these mechanisms 
may not be limited to only elevated Hcys, but other potential pathogenic processes involving 
NADPH oxidase activation. 
 
 
Figure 35. Summary Diagram.  
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7.6 Significance and perspectives 
hHcys is widely recognized as an important, independent risk factor for the progression of 
various sclerotic diseases, including glomerular sclerosis and ESRD. However, the therapeutic 
value of Hcys-lowering interventions is marginal, and this may be attributed to Hcys-induced 
irreversible detrimental effects on glomerular structure and function, on which Hcys-lowering 
therapies would have negligible effects. Thus, our focus has been centered on identifying the 
initiating and promoting mechanisms that occur during early stages of hHcys. In our search of 
early biomarkers, the NLRP3 inflammasome became an attractive target since its major 
functional role is to proteolytically cleave caspases leading to the maturation of pro-
inflammatory cytokines and initiate the innate immune response from the single cell level. The 
presence of activated NLRP3 inflammasomes, perhaps in the urine, may be an early biomarker, 
useful in the diagnosis of early damage and the prevention of more serious glomerular sclerosis. 
Importantly, sustained NLRP3 inflammasome activation may be a perpetual cellular trigger 
responsible for initiating both inflammatory and non-inflammatory-related injury of podocytes, 
ultimately resulting in progressive glomerular disease leading to ESRD. The findings in the 
present study indicate the essential role of NADPH oxidase and the production of ROS, 
specifically O2
•−
 and H2O2, in hHcys-induced NLRP3 inflammasome formation and activation, 
which may be a target to terminate inflammasome activation. TXNIP is also critical in this 
NLRP3 inflammasome-activating mechanism because it is a ROS sensor linking NADPH 
oxidase-derived ROS to NLRP3 inflammasome stimulation.  Together, these findings provide 
the first evidence that targeting either NLRP3 inflammasomes directly or their activating 
mechanisms may be an effective therapeutic strategy for the prevention, detection, and early 
treatment of glomerular sclerosis and other end-stage organ damage resulted from hHcys. 
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  2009  B.S. awarded with University Honors and Summa Cum Laude 
  2011  VCU School of Medicine C.C. Clayton Award 
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  2011  Who‟s Who Among Students in American Universities & Colleges 
  2012  APS Predoctoral Excellence in Renal Research Award Finalist 
2012 VCU Department of Pharmacology & Toxicology Anthony 
Ambrose Best Graduate Student Award 
  2013  VCU Graduate School Travel Grant Recipient 
  2013  VAS Medical Sciences Section Oral Presentation Winner 
  2014  Finalist for ASPET CVP Graduate Student Competition 
  2014  ASPET Graduate Student Travel Award Recipient 
 
4.2 Grants 
2012 F31 Ruth L. Kirschstein National Research Service Award for 
Individual Predoctoral Fellows, NIH National Institute of Aging 
 
4.3 Training 
2013 NIH Clinical Center‟s Clinical and Translational Research Course 
for Ph.D. Students 
 
4.4 Oral Presentations 
2011 Experimental Biology, NADPH oxidase-mediated activation of 
inflammasomes by increased homocysteine in mouse podocytes 
and glomeruli, Washington DC 
2011 89
th
 Annual Virginia Academy of Science, NADPH oxidase-
mediated inflammasome activation by elevated homocysteine in 
mouse podocytes and glomeruli, Richmond VA 
2013 91
st
 Annual Virginia Academy of Science, Thioredoxin-interacting 
protein mediates Hcys-induced NLRP3 inflammasome activation in 
mouse podocytes, Blacksburg VA 
2013 Carolina Cannabinoid Collaborative Conference, Inhibitory action 
of prostamide E2 on homocysteine-induced NLRP3 inflammasome 
activation and podocyte damage, Richmond VA 
2014 Experimental Biology, Contribution of guanine nucleotide 
exchange factor Vav2 to homocysteine-induced NLRP3 
inflammasome activation in mouse podocytes, San Diego CA 
 
4.5 Poster Presentations 
2012 Experimental Biology, Role of different reactive oxygen species in 
homocysteine-induced NALP3 inflammasome activation in mouse 
podocytes; Inhibition of NADPH oxidase attenuates 
hyperhomocysteinemia-induced NALP3 inflammasome activation 
in mouse glomeruli,  San Diego CA 
2013 Experimental Biology, Contribution of reactive oxygen species to 
NLRP3 inflammasome activation in glomeruli of mice with 
hyperhomocysteinemia; Thioredoxin-interacting protein mediates 
Hcys-induced NLRP3 inflammasome activation in mouse 
podocytes, Boston MA 
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2013 American Society of Nephrology, Thioredoxin-interacting protein 
mediates hHcys-induced NLRP3 inflammasome activation in 
glomerular sclerosis, Atlanta GA 
2014 Experimental Biology, Contribution of guanine nucleotide 
exchange factor Vav2 to homocysteine-induced NLRP3 
inflammasome activation in mouse podocytes; Protective effects 
of docosahexaenoic acid metabolites against homocysteine-
induced podocyte injury by inhibition of NLRP3 inflammasomes, 
San Diego CA  
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